

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA.
Initial public offer of equity shares on the main board of BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE", and together with BSE, the "Stock Exchanges") in compliance with Chapter II of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations").



(Please scan this QR code to view the Red Herring Prospectus and the Abridged Prospectus)



MANIPAL HEALTH ENTERPRISES LIMITED

(TO BE LISTED ON THE MAIN BOARD OF BSE AND NSE)

Our Company was originally incorporated in Bengaluru, Karnataka as 'Manipal Health Enterprises Private Limited' as a private limited company under the Companies Act, 1956 pursuant to a certificate of incorporation dated February 15, 2010, issued by the RoC. Subsequently, our Company was converted to a public limited company and the name of our Company was changed to Manipal Health Enterprises Limited pursuant to a resolution passed by our Board and by our Shareholders passed on November 8, 2025 and November 20, 2025, respectively and a fresh certificate of incorporation dated December 24, 2025 was issued by the Registrar of Companies, Central Processing Centre. For details of changes in the name of our Company and registered office of our Company, see *"History and Certain Corporate Matters"* on page 265 of the Red Herring Prospectus dated July 23, 2026 ("RHP").

Corporate Identity Number: U85110KA2010PLC052540
Registered and Corporate Office: The Annexe, #98/2, Rustom Bagh, HAL Airport Road, Bengaluru 560 017, Karnataka, India; **Contact Person:** Sathish Kolar Ramamoorthy, Company Secretary and Compliance Officer
Tel.: +91 80 4936 0300 E-mail: legalcs@manipalhospitals.com Website: www.manipalhospitals.com

THE PROMOTERS OF OUR COMPANY ARE DR. RANJAN RAMDAS PAI, MANIPAL GLOBAL HEALTH SERVICES, MEMG INTERNATIONAL LTD, KANGTO INVESTMENTS PTE. LTD., IMPERIUS HEALTHCARE INVESTMENTS PTE. LTD., AND KABRU INVESTMENTS PTE. LTD.

INITIAL PUBLIC OFFER OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH ("EQUITY SHARES") OF MANIPAL HEALTH ENTERPRISES LIMITED ("COMPANY" OR "ISSUER") FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹[●] MILLION COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹80,000.00 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 21,613,834 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY THE SELLING SHAREHOLDERS, COMPRISING AN OFFER FOR SALE OF UP TO 10,808,861 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY IMPERIUS HEALTHCARE INVESTMENTS PTE. LTD. (THE "PROMOTER SELLING SHAREHOLDER"), UP TO 6,792,002 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY MANIPAL EDUCATION AND MEDICAL GROUP INDIA PRIVATE LIMITED (THE "PROMOTER GROUP SELLING SHAREHOLDER"), UP TO 2,329,667 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY TPG SG MAGAZINE PTE. LTD., UP TO 792,494 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY SEVENTY SECOND INVESTMENT COMPANY LLC, UP TO 405,791 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY AMMAR SDN BHD, UP TO 264,556 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY NOVO HOLDINGS INVEST ASIA A/S, AND UP TO 220,463 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY PHOENIX BEAR INVESTMENTS, LLC, (COLLECTIVELY THE "INVESTOR SELLING SHAREHOLDERS") (THE PROMOTER SELLING SHAREHOLDER, THE PROMOTER GROUP SELLING SHAREHOLDER AND THE INVESTOR SELLING SHAREHOLDERS COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS" AND SUCH EQUITY SHARES OFFERED BY THE SELLING SHAREHOLDERS ("OFFERED SHARES") AND SUCH OFFER, "OFFER FOR SALE", AND TOGETHER WITH THE FRESH ISSUE, THE "OFFER"). THE OFFER INCLUDES A RESERVATION OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2, AGGREGATING UP TO ₹150.00 MILLION (CONSTITUTING UP TO [●]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL), FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES ("EMPLOYEE RESERVATION PORTION"). OUR COMPANY, IN CONSULTATION WITH THE BRLMS MAY OFFER A DISCOUNT OF ₹56 PER EQUITY SHARE OF FACE VALUE OF ₹2 EACH, TO ELIGIBLE EMPLOYEES BIDDING IN THE EMPLOYEE RESERVATION PORTION ("EMPLOYEE DISCOUNT"), SUBJECT TO NECESSARY APPROVALS AS MAY BE REQUIRED. THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER SHALL CONSTITUTE [●] % AND [●] % OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY, RESPECTIVELY.

DETAILS OF THE OFFER FOR SALE BY THE SELLING SHAREHOLDERS			
NAME OF THE SELLING SHAREHOLDERS	TYPE	MAXIMUM NUMBER OF EQUITY SHARES OFFERED OF FACE VALUE OF ₹2 EACH / AMOUNT (IN ₹ MILLION)	WEIGHTED AVERAGE COST OF ACQUISITION (IN ₹ PER EQUITY SHARE)**
Imperius Healthcare Investments Pte. Ltd.	Promoter Selling Shareholder	Up to 10,808,861 Equity Shares of face value of ₹2 each aggregating to ₹[●] million	68.73
Manipal Education and Medical Group India Private Limited	Promoter Group Selling Shareholder	Up to 6,792,002 Equity Shares of face value of ₹2 each aggregating to ₹[●] million	102.56
TPG SG Magazine Pte. Ltd.	Investor Selling Shareholder	Up to 2,329,667 Equity Shares of face value of ₹2 each aggregating to ₹[●] million	265.23
Seventy Second Investment Company LLC	Investor Selling Shareholder	Up to 792,494 Equity Shares of face value of ₹2 each aggregating to ₹[●] million	351.81
Ammar Sdn Bhd	Investor Selling Shareholder	Up to 405,791 Equity Shares of face value of ₹2 each aggregating to ₹[●] million	355.66
Novo Holdings Invest Asia A/S	Investor Selling Shareholder	Up to 264,556 Equity Shares of face value of ₹2 each aggregating to ₹[●] million	355.53
Phoenix Bear Investments, LLC	Investor Selling Shareholder	Up to 220,463 Equity Shares of face value of ₹2 each aggregating to ₹[●] million	355.53

*As certified by Manian & Rao, Chartered Accountants (FRN: 001983S), by way of their certificate dated July 23, 2026. ^ The average cost of acquisition per Equity Share has been calculated considering only the Equity Shares acquired, allotted or purchased (including acquisitions pursuant to transfers). Equity Shares that have subsequently been disposed off have been excluded from the computation of the average cost of acquisition per Equity Share.

PRICE BAND: ₹560 TO ₹590 PER EQUITY SHARE OF FACE VALUE OF ₹2 EACH.

THE FLOOR PRICE IS 280 TIMES THE FACE VALUE OF THE EQUITY SHARES AND THE CAP PRICE IS 295 TIMES THE FACE VALUE OF THE EQUITY SHARES.

BIDS CAN BE MADE FOR A MINIMUM OF 25 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AND IN MULTIPLES OF 25 EQUITY SHARES OF FACE VALUE OF ₹2 EACH THEREAFTER.

THE PRICE TO EARNINGS RATIO ("P/E") BASED ON DILUTED EPS FOR FISCAL 2026 FOR OUR COMPANY AT THE LOWER END OF THE PRICE BAND (I.E. FLOOR PRICE) IS 73.01 TIMES AND AT THE UPPER END OF THE PRICE BAND (I.E. CAP PRICE) IS 76.92 TIMES AS COMPARED TO THE AVERAGE INDUSTRY PEER GROUP P/E RATIO OF 70.31 TIMES FOR FISCAL 2026.

A DISCOUNT OF ₹56 PER EQUITY SHARE IS BEING OFFERED TO ELIGIBLE EMPLOYEES BIDDING IN THE EMPLOYEE RESERVATION PORTION.

WEIGHTED AVERAGE RETURN ON NET WORTH FOR LAST THREE FINANCIAL YEARS IS 13.80%.

The details of the Fresh Issue, Offer for Sale and the post Offer market capitalization of the Company, each at the Floor Price and the Cap Price, are given below:

Particulars	OFFER SIZE AND MARKET CAPITALIZATION			
	At Floor Price of ₹560 per equity share		At Cap Price of ₹590 per equity share	
	Up to No. of Equity Shares of face value of ₹2 each	Up to Amount (₹ in Million)	Up to No. of Equity Shares of face value of ₹2 each	Up to Amount (₹ in Million)
Fresh Issue	142,886,904	80,000.00	135,619,881	80,000.00
Offer For Sale	21,613,834	12,103.75	21,613,834	12,752.16
Total Offer Size	164,500,738	92,103.75	157,233,715	92,752.16
Post Offer Market Capitalization	1,322,644,225	740,680.77	1,315,377,202	776,072.55

BID/ OFFER PROGRAMME	ANCHOR INVESTOR BID/OFFER PERIOD TUESDAY, JULY 28, 2026
	BID/ OFFER OPENS ON WEDNESDAY, JULY 29, 2026
	BID/ OFFER CLOSSES ON FRIDAY, JULY 31, 2026*

*The UPI mandate end time and date shall be at 5:00 p.m. on Bid/Offer Closing Day.

We operate a pan-India network of multispecialty hospitals delivering comprehensive outpatient services, and complex tertiary and quaternary interventions. We are the largest pan-India multispecialty hospital network by bed capacity as of March 31, 2026 (Source: CRISIL Report). We focus on tertiary and quaternary care, particularly in cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics, and renal sciences ("CONGO-R").

THE OFFER IS BEING MADE THROUGH THE BOOK BUILDING PROCESS IN ACCORDANCE WITH REGULATION 6(2) OF THE SEBI ICDR REGULATIONS. THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON THE MAIN BOARDS OF BSE AND NSE. NSE SHALL BE THE DESIGNATED STOCK EXCHANGE.

- QIB PORTION: NOT LESS THAN 75% OF THE NET OFFER
- NON-INSTITUTIONAL PORTION: NOT MORE THAN 15% OF THE NET OFFER
- RETAIL PORTION: NOT MORE THAN 10% OF THE THE NET OFFER
- EMPLOYEE RESERVATION PORTION OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹150.00 MILLION

IN MAKING AN INVESTMENT DECISION, PROSPECTIVE INVESTORS MUST ONLY RELY ON THE INFORMATION INCLUDED IN THE RHP AND THE TERMS OF THE OFFER, INCLUDING THE RISKS INVOLVED AND NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE OFFER AVAILABLE IN ANY MANNER. IN RELATION TO PRICE BAND, POTENTIAL INVESTORS SHOULD ONLY REFER TO THIS PRICE BAND ADVERTISEMENT FOR THE OFFER AND SHOULD NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION AVAILABLE IN ANY MANNER IN RELATION TO THE VALUATION OF THE COMPANY AS THESE ARE NOT ENDORSED, PUBLISHED OR CONFIRMED EITHER BY THE COMPANY OR THE BOOK RUNNING LEAD MANAGERS ("BRLMs").

In accordance with the recommendation of the Committee of Independent Directors of our company, pursuant to their resolution dated July 23, 2026, the above provided Price Band is justified based on Quantitative factors/ Key performance indicators disclosed in the “Basis for Offer Price” section on page 158 of the RHP vis-a-vis the weighted average cost of acquisition (“WACA”) of primary and secondary transaction(s), as applicable, disclosed in the “Basis for Offer Price” section beginning on page 158 of the RHP and provided below in this advertisement.

RISK TO INVESTORS

For details, refer to section titled “Risk Factors” on page 34 of the RHP.

- Geographical Concentration Risk:** As of March 31, 2026, we operated 49 hospitals in India of which we operate 19 hospitals in Karnataka. A substantial portion of our revenue from operations is derived from Karnataka. Any loss of business or disruption in the operations of these hospitals or geopolitical or policy changes in Karnataka could have a material adverse effect on our business, financial condition, results of operations, cash flows and prospects.

Particulars	Fiscal									
	2026					2025				2024
	Pro Forma Financial Information		Restated Consolidated Financial Information			Pro Forma Financial Information		Restated Consolidated Financial Information		Restated Consolidated Financial Information
	(₹ million)	% of revenue from operations	(₹ million)	% of revenue from operations		(₹ million)	% of revenue from operations	(₹ million)	% of revenue from operations	(₹ million) % of revenue from operations
Karnataka	47,953.84	43.85%	47,953.84	46.40%		42,485.77	45.86%	42,485.77	51.55%	37,018.36 59.98%
Eastern India ⁽¹⁾	23,171.64	21.19%	23,171.64	22.42%		18,269.63	19.72%	18,269.63	22.17%	6,873.29 11.14%
Rest of India ⁽²⁾	20,320.78	18.58%	20,320.78	19.66%		17,017.75	18.37%	17,017.75	20.65%	14,389.32 23.31%
Maharashtra & Goa	17,909.92	16.38%	11,911.25	11.52%		14,862.41	16.05%	4,649.35	5.63%	3,435.35 5.57%
Revenue from operations	109,356.18	100.00%	103,357.51	100.00%		92,635.56	100.00%	82,422.50	100.00%	61,716.32 100.00%

Continued on next page...

...continued from previous page.

Notes:

⁽¹⁾ Eastern India includes West Bengal, Odisha, Jharkhand and Sikkim.

⁽²⁾ Rest of India includes Delhi, Andhra Pradesh, Rajasthan, Uttar Pradesh, Haryana, Punjab and Tamil Nadu

2. Patient Volume and Occupancy Risk: We primarily generate revenue from inpatient care at our hospitals. Patient volume and occupancy rates may be impacted by healthcare talent availability, service offerings, patient demand and competitive pressures. Any inability to maintain or improve our admissions and hospital occupancy rates could adversely affect our business, financial condition, results of operations, cash flows and prospects.

Particulars	Fiscal				
	2026		2025		2024
	Pro Forma Financial Information	Restated Consolid- ated Financial Information	Pro Forma Financial Information	Restated Consolid- ated Financial Information	Restated Consolid- ated Financial Information
Inpatient volume ⁽¹⁾ (in footfalls)	578,099	527,227	522,575	439,724	330,725
Revenue from operations (₹ in million)	109,356.18	103,357.51	92,635.56	82,422.50	61,716.32
Occupancy (%) ⁽²⁾	64.45%	64.47%	66.19%	67.09%	65.32%

Notes:

⁽¹⁾ Inpatient volume refers to the total number of patients discharged after clinical treatment that required the use of an inpatient or day-care bed, including patients who stay overnight as well as day-care patients who are admitted and discharged on the same day.

⁽²⁾ Occupancy (%) is defined as the number of the periodic average of occupied beds divided by the number of operational beds.

3. Specialty Wise Revenue Risk: We derive a significant portion of our revenues from the CONGO-R specialties. Any negative changes in the demand for these specialties, due to unavailability of preferred doctors, shifts in patient preferences, advancements in alternative treatments, increased competition or otherwise, could adversely impact our business, results of operations and financial condition.

Particulars	Fiscal				
	2026		2025		2024
	Pro Forma Financial Information	Restated Consolid- ated Financial Information	Pro Forma Financial Information	Restated Consolid- ated Financial Information	Restated Consolid- ated Financial Information
Revenue from CONGO-R (₹ million)	53,527.80	50,309.54	44,597.13	39,152.05	28,396.46
Gross inpatient revenue (₹ million)	83,531.38	78,244.98	71,817.32	62,581.18	46,126.93
Revenue from CONGO-R as a percentage of gross inpatient revenue (%)	64.09%	64.30%	62.10%	62.56%	61.55%

4. Risk related to objects of the offer: We propose to utilize an estimated amount of ₹55,527.59 million from the Net Proceeds towards redemption of the outstanding Non-Convertible Debentures issued by our Subsidiary, MHPL (“**MHPL NCDs**”). Of these Net Proceeds, ₹25,201.79 million will be utilized to redeem the MHPL NCDs held by DBS Bank Ltd., the parent company of DBS Bank India Limited. DBS Bank India Limited is also deemed to be an “associate” of Imperius Healthcare Investments Pte. Ltd. (one of our Promoters and Selling Shareholders) in terms of Regulation 21A of SEBI Merchant Bankers Regulations. The MHPL NCDs have been issued in the ordinary course of business.

5. Acquisition and Integration Risk: We have in the past and may in the future acquire businesses or enter into strategic partnerships or alliances. We acquired 89.98% of the share capital of Sahyadri Hospitals Private Limited (“**SHPL**”) between October 2025 and December 2025 and are in the process of integrating SHPL into our operations. Any delays, difficulties or failure in achieving the anticipated benefits of the acquisition, including integration, rebranding, regulatory approvals, retention of key personnel, realization of synergies and management of unforeseen liabilities and costs, may adversely affect our business, financial condition and results of operations.

6. Legal and Regulatory risk: We are exposed to legal claims, regulatory actions and liabilities arising from the provision of healthcare services, including alleged medical negligence, operational incidents and equipment-related failures. Any such events, as well as hospital quarantines or sterilizations, may adversely affect our reputation, operations, financial condition and results of operations.

7. Regulatory Compliances Risk: We are required to obtain, renew and maintain statutory and regulatory permits, licenses and accreditations and comply with prescribed quality standards. We must obtain and continually maintain multiple approvals, licenses, registrations and permits from governmental and regulatory authorities for, among other

things, the establishment and operation of hospitals, the procurement and operation of medical and other equipment, the storage and sale of drugs and to maintain our accreditations.

8. Payor mix related Risk: We derived 49.68%, 49.18% and 49.45% of our gross inpatient revenue from insurance and third-party administrators in Fiscals 2026, 2025 and 2024, respectively. Termination, non-renewal, delay or difficulties in collection or any breach of the conditions of our contracts with insurance and third-party administrators, as well as from government and other non-cash payors, could have a material adverse impact on our business, financial condition, results of operations, cash flows and prospects.

9. Subsidiaries Losses: Our Subsidiaries have incurred net losses after tax in the past and may continue to experience such losses in the future.

Particulars	Fiscal		
	2026	2025	2024
	(in ₹ million)		
Manipal Health Enterprises International Pte. Ltd.	(0.60)	25.68	(1.60)
HealthMap Diagnostics Private Limited	98.62	(12.37)	(622.95)
Manipal Hospitals Eastern India Private Limited (formerly known as Medica Hospitals Private Limited) ⁽¹⁾	405.29	(103.75)	Nil
Manipal Hospitals Bengal Private Limited (formerly known North Bengal Clinic Private Limited) ⁽¹⁾	(28.11)	10.88	NA
HCMCT Silo ⁽²⁾	622.94	(108.86)	(283.39)
Sahyadri Hospitals Private Limited ⁽³⁾	(485.34)	NA	NA
Sahyadri Karad Hospitals Private Limited ⁽³⁾	(7.85)	NA	NA

Notes:

⁽¹⁾ Manipal Hospitals Eastern India Private Limited (formerly known as Medica Hospitals Private Limited) was acquired by our Company in Fiscal 2025. Accordingly, its financial information for Fiscal 2025 is for the period from July 1, 2024 to March 31, 2025, and its financial information has not been included in Fiscal 2024.

⁽²⁾ HCMCT Silo is not a subsidiary of the Company, but is consolidated as a deemed separate entity under Ind AS 110. For further details, see “Restated Consolidated Financial Information - Note 1(b)(i)” on page 341 of the RHP.

⁽³⁾ Sahyadri Hospitals Private Limited and Sahyadri Karad Hospitals Private Limited were acquired by our Company on October 3, 2025. Accordingly, their financial information for Fiscal 2026 reflects the period from October 3, 2025 to March 31, 2026 and was not included in Fiscal 2025 and Fiscal 2024.

10. Doctors and Employee cost: Our business is exposed to significant employee benefit and doctor professional fee costs. Any inability to attract and retain healthcare professionals on commercially favorable terms or pass on rising personnel costs to patients, insurers and TPAs may adversely affect our margins, profitability and financial performance.

Particulars	Fiscal					
	2026		2025		2024	
	Amount (₹ million)	% of revenue from operations	Amount (₹ million)	% of revenue from operations	Amount (₹ million)	% of revenue from operations
Doctors profess- ional fees	23,485.14	22.72%	17,584.26	21.33%	13,248.27	21.47%
Employee benefit expenses	14,900.35	14.42%	12,194.12	14.79%	8,570.39	13.89%

11. Offer related risk: While our Company will receive proceeds from the Fresh Issue, it will not receive any proceeds from the Offer for Sale.

12. The Offer is being made pursuant to Regulation 6(2) of the SEBI ICDR Regulations as our Company has Net Tangible Assets less than ₹30 million in the Fiscal 2026, on a restated and consolidated basis.

13. Pursuant to the share purchase agreement dated March 16, 2026, TPG SG Magazine Pte. Ltd., one of our Investor Selling Shareholders, has transferred 5,123,543 Equity Shares to MRMSI (member of Promoter Group) at a price of ₹58.45 per Equity Share on July 14, 2026, which may be significantly lower than the Offer Price.

14. Our Price/Earning (P/E) ratio based on diluted EPS for Financial Year 2026 is 73.01 and 76.92 times at the lower and upper end of the Price Band.

15. Weighted Average Return on Net Worth for Financial Year ended 2026, 2025 and 2024 is 13.80%

16. The average cost of acquisition of Equity Shares for Selling Shareholders ranges from ₹68.73 per Equity Share to ₹355.66 per Equity Share and the Offer Price at upper end of the Price Band is ₹590 per Equity Share.

17. Weighted average cost of acquisition of all equity shares transacted in one year, 18 months and three years preceding the date of the Red Herring Prospectus.

Continued on next page...

...continued from previous page.

Period	Weighted Average Cost of Acquisition (in ₹)*@	Cap Price is 'X' times the Weighted Average Cost of Acquisition*	Range of acquisition price: Lowest Price – Highest Price (in ₹)#
Last one year preceding the date of the Red Herring Prospectus	580.41	1.02	58.45- 692.68
Last 18 months preceding the date of the Red Herring Prospectus	21.01	28.08	58.45-692.68*
Last three years preceding the date of the Red Herring Prospectus	72.04	8.19	58.45-1,066.97*

*As certified by Manian & Rao, Chartered Accountants (FRN: 001983S), by way of their certificate dated July 23, 2026.
#@Computed based on the equity shares acquired/allotted/purchased (including acquisition pursuant to transfer). However, the equity shares disposed off have not been considered while computing number of Equity Shares acquired.
* Computed based on the allotment/ acquisition of Equity Shares excluding Equity Shares acquired pursuant to the bonus issue of Equity Shares.

Notes:
1.Effect of sub-division and bonus issuance has been given while calculating weighted average cost of acquisition and effect of sub-division has been given while calculating the range of acquisition price

18. The seven BRLMs associated with the Offer have handled 76 public issues in the past three years, out of which 18 issues have closed below the issue price on the listing date

Name of BRLMs	Total Public Issues	Issues closed below IPO price on the day of listing
Kotak Mahindra Capital Company Limited*	8	3
Axis Capital Limited*	24	5
Goldman Sachs (India) Securities Private Limited*	0	0
Jefferies India Private Limited*	3	1
J.P. Morgan India Private Limited*	1	0
UBS Securities India Private Limited*	1	0
DBS Bank India Limited**	0	0
Common issues of above BRLMs	39	9
Total	76	18

* Issues handled where there were no common BRLMs
**DBS Bank India Limited is deemed to be an “associate” of Imperius Healthcare Investments Pte. Ltd. (one of our Promoters and Selling Shareholders) in terms of Regulation 21A of SEBI Merchant Bankers Regulations and has undertaken to be associated only with respect to the marketing of the Offer in compliance with Regulation 21A of SEBI Merchant Bankers Regulations. Further, DBS Bank India Limited has signed the due diligence certificate and has been disclosed as a Book Running Lead Manager in the Red Herring Prospectus

Additional Information for Investors

1. Our Company has not undertaken pre-IPO placement from the DRHP till date.
2. The Promoters or members of the Promoter Group have not undertaken any transaction of shares aggregating up to 1% or more of the paid-up equity share capital of the Company from the DRHP till date.
3. The aggregate pre-Offer and post-Offer shareholding of our Promoters (including the Promoter Selling Shareholder), members of the Promoter Group, the additional top 10 Shareholders and other public Shareholders is set out below:

Sr. No	Name of the Shareholders	Pre-Offer Shareholding as on date of the Red Herring Prospectus		Post-Offer Shareholding as at Allotment ⁽¹⁾			
		Number of Equity Shares of face value of ₹2 each	Percentage of the pre-Offer paid-up Equity Share capital (%)	At the lower end of the Price Band (₹560)		At the upper end of the Price Band (₹590)	
				Number of Equity Shares of face value of ₹2 each	Percentage of the post-Offer paid-up equity share capital (%)	Number of Equity Shares of face value of ₹2 each	Percentage of the post-Offer paid-up equity share capital (%)
Promoters							
1.	Dr. Ranjan Ramdas Pai	2,180,790	0.18	2,180,790	0.16	2,180,790	0.17
2.	Manipal Global Health Services	232,147,755	19.68	232,147,755	17.55	232,147,755	17.65
3.	Kangto Investments Pte. Ltd.	312,102,855	26.45	312,102,855	23.60	312,102,855	23.73
4.	Imperius Healthcare Investments Pte. Ltd. [#]	209,609,340	17.77	198,800,479	15.03	198,800,479	15.11
5.	Kabru Investments Pte. Ltd.	68,234,415	5.78	68,234,415	5.16	68,234,415	5.19
Total (A)		824,275,155	69.87	813,466,294	61.50	813,466,294	61.84
Members of Promoter Group (excluding the Promoters)							
1	Cypress Holdings	49,172,520	4.17	49,172,520	3.72	49,172,520	3.74
2	Manipal Education and Medical Group India Private Limited [#]	63,384,915	5.37	56,592,913	4.28	56,592,913	4.30
3	MEMG International India Private Limited	23,820,811	2.02	23,820,811	1.80	23,820,811	1.81
4	Manipal Research & Management Services International	5,123,543	0.43	5,123,543	0.39	5,123,543	0.39
Total (B)		141,501,789	12.00	134,709,787	10.19	134,709,787	10.24
Additional top 10 Shareholders							
1.	TPG SG Magazine Pte. Ltd.*	122,029,477	10.34	119,699,810	9.05	119,699,810	9.10
2.	Seventy Second Investment Company LLC	43,254,210	3.67	42,461,716	3.21	42,461,716	3.23
3.	Ammar Sdn Bhd	22,148,025	1.88	21,742,234	1.64	21,742,234	1.65
4.	Novo Holdings Invest Asia A/S	14,439,405	1.22	14,174,849	1.07	14,174,849	1.08
5.	Phoenix Bear Investments, LLC	12,032,835	1.02	11,812,372	0.89	11,812,372	0.90
6.	Ashu Singal	76,425	0.01	76,425	0.01	76,425	0.01
Total (C)		213,980,377	18.14	209,967,406	15.87	209,967,406	15.96
Other public Shareholders							
1.	Nil	Nil	Nil	164,500,738	12.44	157,233,715	11.96
Total (D)		Nil	Nil	164,500,738	12.44	157,233,715	11.96
Total (A+B+C+D) = E		1,179,757,321	100.00	1,322,644,225	100.00	1,315,377,202	100.00

⁽¹⁾ Assuming full subscription in the Offer. The post-Offer shareholding details as at Allotment will be based on the actual subscription and the Offer Price and updated in the Prospectus, subject to finalization of the Basis of Allotment. Also, this table assumes there is no transfer of shares by these shareholders between the date of the advertisement and Allotment (if any such transfers occur prior to the date of the Prospectus, it will be updated in the shareholding pattern in the Prospectus).
* Also a Selling Shareholder.
* Pursuant to a share purchase agreement dated March 16, 2026, entered into between MRMSI and TPG SG Magazine Pte. Ltd., TPG SG Magazine Pte. Ltd. has transferred 5,123,543 Equity Shares of face value of ₹2 each, to MRMSI. For further details, see “History and certain corporate matters - Details of subsisting shareholders agreements – Inter-se agreements between shareholders – Upside sharing agreement dated March 16, 2026, entered into between Manipal Research & Management Services International and TPG SG Magazine Pte. Ltd.” on page 289 of the RHP.

BASIS FOR OFFER PRICE



The “Basis for Offer Price” on page 158 of the RHP has been updated with the above Price Band. Please refer to the website of the BRLMs: https://investmentbank.kotak.com, www.axiscapital.co.in, www.goldmansachs.com, www.jefferies.com, www.jpmlpi.com, www.ubs.com/indiaoffers, https://go.dbs.com/ipo for the “Basis of Offer Price” updated for the above Price Band.
(You may scan the QR code for accessing the website of Kotak Mahindra Capital Company Limited)

The Price Band and the Offer Price will be determined by our Company, in consultation with the BRLMs, on the basis of assessment of market demand for the Equity Shares offered through the Book Building Process and on the basis of quantitative and qualitative factors as described below. The face value of the Equity Shares is ₹2 each and Floor Price is 280 times the face value and the Cap Price is 295 times the face value. Bidders should also see “Risk Factors”, “Summary of Restated Consolidated Financial Information”, “Our Business”, “Restated Consolidated Financial Information”, “Pro Forma Financial Information” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” beginning on pages 34, 94, 223, 322, 427 and 550 of the RHP, respectively, to have an informed view before making an investment decision.

Qualitative Factors
Some of the qualitative factors and our strengths which form the basis for computing the Offer Price are on page 158 of the RHP.
Quantitative Factors
Some of the information presented below relating to our Company is derived from the Restated Consolidated Financial Information. For details, see “Restated Consolidated Financial Information” and “Other Financial Information” beginning on pages 322 and 545 of the RHP respectively.
Some of the quantitative factors which may form the basis for computing the Offer Price are as follows:

A. Basic and Diluted Earnings Per Equity Share (“EPS”) (face value of each Equity Share is ₹2):

Financial Year Ended	Basic EPS (in ₹)	Diluted EPS (in ₹)	Weight
March 31, 2026	7.71	7.67	3
March 31, 2025	9.25	9.25	2
March 31, 2024	5.27	5.25	1
Weighted Average	7.82	7.79	

Notes:
1. Basic earnings per share is calculated by dividing the profit for the year attributable to equity shareholders of our Company by the weighted average number of Equity Shares outstanding during the year.
2. Diluted earnings per share is calculated by dividing profit for the year attributable to equity shareholders by the weighted average number of Equity Shares outstanding during the year adjusted for the effects of all dilutive potential Equity Shares.
3. Weighted average = Aggregate of year-wise weighted EPS divided by the aggregate of weights i.e., (EPS x Weight) for each year/Total of weights.
4. During the financial year ended March 31, 2025, our Company sub-divided its equity shares by reducing the nominal value of each of the equity shares from ₹ 10 to ₹ 2. Accordingly, each equity share of ₹ 10 was sub-divided into five equity shares of ₹ 2 each. The Earnings per Equity Share (basic and diluted) has been calculated after giving effect to such bonus issuance in all periods presented.
5. During the financial year ended March 31, 2026, our Company had undertaken a bonus issue of Equity Shares of face value of ₹2 each in the ratio of 2:1 i.e. two equity shares for every one equity share held by the existing Shareholders.

B. Price/Earning (“P/E”) ratio in relation to Price Band of ₹560 to ₹590 per Equity Share:

Particulars	P/E at the Floor Price (number of times)	P/E at the Cap Price (number of times)
Based on basic EPS for financial year ended March 31, 2026	72.63	76.52
Based on diluted EPS for financial year ended March 31, 2026	73.01	76.92

C. Industry Peer Group P/E ratio

Particulars	P/E Ratio
Highest	74.55
Lowest	66.15
Average	70.31

Notes:
1. The highest and lowest industry P/E shown above is based on the peer set provided below under “Comparison with listed industry peers” The industry average has been calculated as the arithmetic average P/E of the peer set.
2. P/E ratio for the peer group has been computed based on the closing market price of equity shares on NSE as on July 21, 2026, divided by diluted EPS for fiscal ended March 31, 2026.

D. Return on Net Worth (“RoNW”)

Financial Year Ended	RoNW (%)	Weight
March 31, 2026	10.57	3
March 31, 2025	18.16	2
March 31, 2024	14.75	1
Weighted Average	13.80	

Notes:
1. Return on Net Worth is calculated as Profit/(loss) for the year attributable to owners of the Company divided by Net Worth as of at the end of the respective year
2. Net Worth has been defined as the aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account and debit or credit balance of restated consolidated statement of profit and loss, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, as per the restated consolidated statement of assets and liabilities, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation. Further, Net Worth is calculated as the sum of equity share capital, other equity, foreign currency translation reserve, and adjustments for re-measurement of the defined benefit plan.
3. Weighted average means aggregate of year-wise weighted RoNW divided by the aggregate of weights i.e. (RoNW x weight) for each year/total of weights.
For a reconciliation of Non-GAAP measures, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations- Non - GAAP Financial Measures” on page 561 of the RHP.

E. Net Asset Value (“NAV”) per Share of face value of ₹2 each

As derived from the Restated Financial Statements:

Particulars	Amount (₹)
As on March 31, 2026	72.55
After the completion of the Offer	
- At the Floor Price	125.86
- At the Cap Price	126.56
- At the Offer Price*	[•]

* To be determined on conclusion of the Book Building Process and to be populated in the Prospectus
Notes:
1. Net Asset Value per share is calculated as net worth at the end of the year divided by number of equity shares outstanding at the end of the year. Number of equity shares outstanding at the end of the year is an aggregate of outstanding number of equity shares considering dilutive number of shares.
2. Net Worth has been defined as the aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account and debit or credit balance of restated consolidated statement of profit and loss, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, as per the restated consolidated statement of assets and liabilities, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation. Further, Net Worth is calculated as the sum of equity share capital, other equity, foreign currency translation reserve, and adjustments for re-measurement of the defined benefit plan.
3. During the financial year ended March 31, 2025, our Company sub-divided its equity shares by reducing the nominal value of each of the equity shares from ₹10 to ₹2. Accordingly, each equity share of ₹10 was sub-divided into five equity shares of ₹2 each. Further, during the financial year ended March 31, 2026, the Company had undertaken a bonus issue of equity shares in the ratio of 2:1 i.e. two equity shares for every one equity share held to the existing shareholders. The Net Asset Value has been calculated after giving effect to such sub-division and bonus issuance.

For a reconciliation of Non-GAAP measures, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations- Non - GAAP Measures” on page 561 of the RHP.

Continued on next page...

...continued from previous page.

F. Comparison with listed industry peers

The following table provides a comparison of the accounting ratios of our Company with our peer group. The peer group has been determined on the basis of companies listed on Indian stock exchanges and globally, whose business profile is comparable to our businesses in terms of our size and our business model. The accounting ratios below have been calculated after giving effect to the consequent increase in the number of equity shares of the Company, to the extent applicable, assuming that the outstanding options granted under ESOP Plan 2024 will be exercised:

Name of the company	Face value (₹) per equity share)	Revenue from operations (₹ in million)	EPS (₹)		P/E	NAV (₹ per share)	Return on Net Worth (%)
			Basic	Diluted			
Our Company*	2	103,357.51	7.71	7.67	●†	72.55	10.57
Listed Peers							
Apollo Hospitals Enterprise Ltd	5	252,285.00	135.04	134.94	66.15	NA**	NA**
Fortis Healthcare Ltd	10	91,278.40	13.80	13.80	70.22	NA**	NA**
Max Healthcare Institute Ltd	10	100,650.00	14.83	14.76	74.55	NA**	NA**

Source: All the financial information for listed industry peers mentioned above is on a consolidated basis and is sourced from the financial results of the respective company for the year ended March 31, 2026 submitted to stock exchanges.

* Financial information of our Company has been derived from the Restated Consolidated Financial Information.

† To be included in respect of our Company in the Prospectus based on the Offer Price.

** Data not reported by Listed Peers in its audited consolidated financial statement, annual report, investor presentation or website and hence has been mentioned as 'NA' i.e. Not Available

Notes:

- (i) Basic and Diluted EPS refers to the Basic and Diluted EPS sourced from the financial statements of the companies respectively for the Fiscal ended March 31, 2026
- (ii) Price/earnings ratio for the peers has been computed based on the closing market price of equity shares on NSE as on July 21, 2026 divided by the diluted earnings per share for financial year ended March 31, 2026.
- (iii) Net Asset Value per share is calculated as net worth at the end of the year divided by number of equity shares outstanding at the end of the year. Number of equity shares outstanding at the end of the year is an aggregate of outstanding number of equity shares considering dilutive number of shares.
- (iv) Return on Net Worth is calculated as Profit/(loss) for the year attributable to owners of the Company divided by Net Worth as of at the end of the respective year.
- (v) Net Worth has been defined as the aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account and debit or credit balance of restated consolidated statement of profit and loss, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, as per the restated consolidated statement of assets and liabilities, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation. Further, Net Worth is calculated as the sum of equity share capital, other equity, foreign currency translation reserve, and adjustments for re-measurement of the defined benefit plan.

For a reconciliation of Non-GAAP measures, see "Management's Discussion and Analysis of Financial Condition and Results of Operations- Non - GAAP Measures" on page 561 of the RHP.

K. Weighted average cost of acquisition ("WACA"), floor price and cap price

a) Price per share of our Company (as adjusted for corporate actions, including bonus issuances) based on primary issuances of Equity Shares or convertible securities (excluding issuance of Equity Shares pursuant to a bonus issue and ESOP Plan 2024)during the 18 months preceding the date of the Red Herring Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of our Company (calculated based on the pre-Offer capital before such transaction(s)), in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Primary Issuances")

Our Company has not issued any Equity Shares or convertible securities, during the 18 months preceding the date of the Red Herring Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of our Company (calculated based on the pre-Offer capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

b) Price per share of our Company (as adjusted for corporate actions, including bonus issuances) based on secondary sale or acquisition of equity shares or convertible securities (excluding gifts) involving the Selling Shareholders or other shareholders with the right to nominate directors on our Board during the 18 months preceding the date of filing of the Red Herring Prospectus, where the acquisition or sale is equal to or more than 5% of the fully diluted paid-up share capital of our Company (calculated based on the pre-Offer capital before such transaction(s) and excluding ESOPs granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Secondary Transactions")

There have been no secondary sale/ acquisitions of Equity Shares or preference shares, where the Selling Shareholders having the right to nominate Director(s) on our Board, is a party to the transaction, during the 18 months preceding the date of the Red Herring Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of our Company (calculated based on the pre-Offer capital before such transaction(s)), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

c) Since there were no primary or secondary transactions of equity shares of the Company during the 18 months preceding the date the RHP, the information has been disclosed for price per share of the Company based on the last five primary or secondary transactions where the Promoters, Promoter Group, the Selling Shareholders or shareholder(s) having the right to nominate director(s) on our Board, are a party to the transaction, not older than three years prior to the date of filing of the Red Herring Prospectus irrespective of the size of the transaction:

The details of last five primary/secondary transactions in the last three years preceding the date of the Red Herring Prospectus are as follows:

Date of transfer/ allotment	Name of transferor	Name of transferee/ Allottee	No. of shares transacted**	Issue/ Transfer price per share (₹)**A	Face Value (₹)*	Nature of Transfer/ allotment	Nature of consid- eration	Total consideration (₹)	Price per security (₹)
January 31, 2024	Kabru Investments Pte. Ltd.	Seventy Second Investment Company LLC	42,450,225	351.86	10	Transfer	Cash	14,936,432,419.00	5,277.86
May 28, 2024	NA	Kabru Investments Pte. Ltd.	1,679,970	349.07	10	Allotment pursuant to Rights issue	Cash	586,421,528.00	5,236.00
	NA	Kanglo Investments Pte. Ltd.	5,801,175	349.07			Cash	2,024,996,820.00	5,236.00
	NA	Novo Holdings Invest Asia A/S	268,395	349.07			Cash	93,687,748.00	5,236.00
	NA	Seventy Second Investment Company , LLC	803,985	349.07			Cash	280,644,364.00	5,236.00
	NA	Ashu Singal	1,425	349.07			Cash	497,420.00	5,236.00

Date of transfer/ allotment	Name of transferor	Name of transferee/ Allottee	No. of shares transacted**	Issue/ Transfer price per share (₹)**A	Face Value (₹)*	Nature of Transfer/ allotment	Nature of consid- eration	Total consideration (₹)	Price per security (₹)
May 30, 2024	NA	Imperius Healthcare Investments Pte. Ltd.	3,896,085	349.07	10	Allotment pursuant to Rights issue	Cash	1,359,993,404.00	5,236.00
	NA	TPG SG Magazine Pte. Ltd.	2,363,445	349.07			Cash	824,999,868.00	5,236.00
	NA	Phoenix Bear Investments, LLC	223,665	349.07			Cash	78,073,996.00	5,236.00
June 12, 2024	NA	Dr. Ranjan Ramdas Pai	40,530	349.07	10	Allotment pursuant to Rights issue	Cash	14,147,672.00	5,236.00
June 19, 2024	NA	Manipal Education and Medical Group India Private Limited	1,178,160	349.07	10	Allotment pursuant to Rights issue	Cash	411,256,384.00	5,236.00
June 20, 2024	NA	Cypress Holdings	5,229,000	349.07	10	Allotment pursuant to Rights issue	Cash	1,825,269,600.00	5,236.00
August 20, 2024	Kabru Investments Pte. Ltd.	Ammar Sdn Bhd	22,148,025	355.66	10	Transfer	Cash	7,877,075,220.00	5,334.83
March 12, 2026	NA	MEMG International India Private Limited	23,820,811	692.68	2	Allotment of Equity Shares of face value of ₹2 each pursuant to the settlement under the Restated Brand License Agreement	Cash	16,500,200,056.16	692.68
July 14, 2026	TPG SG Magazine Pte. Ltd.	Manipal Research and Management Services International	5,123,543	58.45	2	Transfer	Cash	299,450,594.18	58.45

*Pursuant to resolutions dated March 18, 2025 and March 25, 2025, passed by our Board and the Shareholders respectively, each equity share of face value of ₹10 each has been split into five Equity Shares of face value of ₹2 each. Accordingly, the issued, subscribed and paid-up equity share capital of our Company was sub-divided from ₹770,624,340 divided into 77,062,434 equity shares of face value of ₹10 each to ₹770,624,340 divided into 385,312,170 Equity Shares of face value of ₹2 each.

** Adjusted for split and bonus issue

A Amount rounded off upto two decimal places.

With reference to (a), (b) and (c) above weighted average cost of acquisition, floor price and cap price:

Types of transactions	Weighted average cost of acquisition (₹ per Equity Share)	Floor price (i.e. INR 560)	Cap price (i.e. INR 590)
Weighted average cost of acquisition for Primary Issuances	Nil	N.A.	N.A.
Weighted average cost of acquisition for Secondary Transactions	Nil	N.A.	N.A.
Since there were no primary or secondary transactions of equity shares of the Company during the 18 months preceding the date of filing of the Red Herring Prospectus, the information has been disclosed for price per share of the Company based on the last five primary or secondary transactions where the Promoters, Promoter Group, the Selling Shareholders or shareholder(s) having the right to nominate director(s) on our Board, are a party to the transaction, not older than three years prior to the date of filing of the Red Herring Prospectus irrespective of the size of the transaction	409.58	1.37	1.44

L. Justification for Basis of Offer price

Detailed explanation for Offer Price/Cap Price along with our Company's KPIs and financial ratios for the periods presented in the Restated Consolidated Financial Information and in view of the external factors which may have influenced the pricing of the issue, if any

- India's largest multispecialty hospital group by bed capacity with pan-India presence and leadership in our three key regions
- Only private hospital chain network in India with leadership in three metros (Bengaluru, Kolkata and Pune) with a balanced and diversified presence across metros and non-metros
- Widely recognized brand and network of choice for patients, doctors and healthcare professionals
- Advanced infrastructure and medical equipment, with a strong focus on clinical excellence
- Track record of delivering industry leading growth with strong profitability and efficiency metrics
- Repeatable playbook for integrating and scaling transformative acquisitions to improve access to quality healthcare
- Experienced leadership team with marquee institutional shareholder support

Investors should read the abovementioned information along with "Risk Factors", "Our Business", "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Restated Consolidated Financial Information" on pages 34, 223, 550 and 322 of the RHP, respectively, to have a more informed view. The trading price of Equity Shares could decline due to factors mentioned in "Risk Factors" on page 34 of the RHP and you may lose all or part of your investments.

AN INDICATIVE TIMETABLE IN RESPECT OF THE OFFER IS SET OUT BELOW:

Submission of Bids (other than Bids from Anchor Investors):			Bid/Offer Programme
Bid/Offer Period (except the Bid/Offer Closing Date)			An indicative timetable in respect of the Offer is set out below:
Submission and revision in Bids		Only between 10.00 a.m. and 5.00 p.m. IST	Event
Bid/Offer Closing Date			Indicative Date
Submission of electronic applications (online ASBA through 3-in-1 accounts) for RIBs, Eligible Employees Bidding in the Employee Reservation Portion		Only between 10.00 a.m. and up to 5.00 p.m. IST	BID/OFFER OPENS ON
Submission of electronic application (bank ASBA through online channels like internet banking, mobile banking and syndicate ASBA applications through UPI as a payment mechanism where Bid Amount is up to ₹0.50 million)		Only between 10.00 a.m. and up to 4.00 p.m. IST	BID/OFFER CLOSES ON
Submission of electronic applications (syndicate non-retail, non-individual applications of QIBs and NIIIs)		Only between 10.00 a.m. and up to 3.00 p.m. IST	Finalisation of Basis of Allotment with the Designated Stock Exchange
Submission of Physical Applications (Bank ASBA)		Only between 10.00 a.m. and up to 1.00 p.m. IST	Initiation of refunds (if any, for Anchor Investors)/unblocking of funds from ASBA Account*
Submission of physical applications (syndicate non-retail, non-individual applications where Bid Amount is more than ₹0.50 million)		Only between 10.00 a.m. and up to 12.00 p.m. IST	Credit of Equity Shares to dematerialized accounts of Allottees
Modification/Revision/cancelled of Bids			Commencement of trading of the Equity Shares on the Stock Exchanges
Upward revision of Bids by QIBs and Non-Institutional Bidders categories ⁴		Only between 10.00 a.m. and up to 4.00 p.m. IST on Bid/ Offer Closing Date	
Upward or downward revision of Bids or cancellation of Bids by RIBs, Eligible Employees Bidding in the Employee Reservation Portion		Only between 10.00 a.m. and up to 5.00 p.m. IST on Bid/ Offer Closing Date	
*UPI mandate end time shall be 5:00 p.m. on the Bid/ Offer Closing Date.			
⁴ QIBs and Non-Institutional Bidders can neither revise their bids downwards nor cancel/withdraw their bids.			
On the Bid/ Offer Closing Date, the Bids shall be uploaded until:			
(i) 4.00 p.m. IST in case of Bids by QIBs and NIBs, and			
(ii) until 5.00 p.m. IST, in case of Bids by RIBs and Eligible Employees Bidding in the Employee Reservation Portion.			
On Bid/Offer Closing Date, extension of time may be granted by Stock Exchanges only for uploading Bids received RIBs and Eligible Employees under the Employee Reservation Portion, after taking into account the total number of Bids received and as reported by the BRLMs to the Stock Exchanges.			

ASBA* Simple, Safe, Smart way of Application!!!

*Applications Supported by Blocked Amount ("ASBA") is a better way of applying to offers by simply blocking the fund in the bank account.

For further details, check section on ASBA.

Mandatory in public issues. No cheque will be accepted.



UNIFIED PAYMENTS INTERFACE

UPI-Now available in ASBA for Retail Individual Investors and Non Institutional Investor applying in public issues where the application amount is up to ₹ 500,000, applying through Registered Brokers, Syndicate, CDPs & RTAs. UPI Bidders also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Investors are required to ensure that the bank account used for bidding is linked to their PAN. Bidders must ensure that their PAN is linked with Aadhaar and are in compliance with CDBT notification dated February 13, 2020 issued by the Central Board of Direct Taxes and the subsequent press releases, including press release dated June 25, 2021 read with press release dated September 17, 2021, and CDBT circular no. 7 of 2022 dated March 30, 2022, read with press release dated March 28, 2023, and any subsequent press release in this regard.

ASBA has to be availed by all the investors except Anchor Investors. UPI may be availed by (i) Retail Individual Investors in the Retail Portion; (ii) Eligible Employees in the Employee Reservation Portion (iii) Non-Institutional Investors with an application size of up to ₹0.50 million in the Non-Institutional Portion. For more details on the ASBA and UPI process, please refer to the details given in the Bid Cum Application Form and the Abridged Prospectus and also please refer to the section "Offer Procedure" on page 641 of the RHP. The process is also available on the website of Association of Investment Bankers of India ("AIBI") and Stock Exchanges and in the General Information Document. The Bid Cum Application Form and the Abridged Prospectus can be downloaded from the websites of the Stock Exchanges and can be obtained from the list of banks that is displayed on the website of SEBI at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFp=yes&intmId=35 and <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFp=yes&intmId=43>, respectively as updated from time to time. For the list of UPI apps and banks live on IPO, please refer to the link: www.sebi.gov.in. UPI Bidders Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI, as updated from time to time. Axis Bank Limited and Kotak Mahindra Bank Limited have been appointed as the Sponsor Banks for the Offer, in accordance with the requirements of SEBI circular dated November 1, 2018 as amended. For Offer related queries, please contact the BRLMs on their respective email IDs as mentioned below. For UPI related queries, investors can contact NPCI at the toll free number: 18001201740 and mail id: ipo.npci@npci.org.in.

THE EQUITY SHARES OF OUR COMPANY WILL GET LISTED ON THE MAIN BOARD PLATFORMS OF BSE AND NSE.

In case of any revision in the Price Band, the Bid/ Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/ Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company, in consultation with the BRLMs, for reasons to be recorded in writing, may extend the Bid/ Offer Period for a minimum of one Working Day, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and by intimation to and by intimation to Self-Certified Syndicate Banks ("SCSBs"), the Designated Intermediaries and the Sponsor Banks, as applicable.

The Offer is being made in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations. The Offer is being made through the Book Building Process in accordance with Regulation 6(2) of the SEBI ICDR Regulations wherein in terms of Regulation 32(2) of the SEBI ICDR Regulations, not less than 75% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs", and such portion, the "QIB Portion") provided that our Company in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations, of ("Anchor Investor Portion"), of which 40% of such Anchor Investor Portion shall be reserved in the following manner i) 33.33% shall be reserved, for allocation to domestic Mutual Funds; and (ii) 6.67% shall be reserved for Life Insurance Companies and Pension Funds, subject to valid Bids being received from domestic Mutual Funds, Life Insurance Companies and Pension Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription in (i) above, the allocation may be made to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (excluding the Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. If at least 75% of the Net Offer cannot be Allotted to QIBs, then the entire application money will be refunded forthwith. Further, not more than 15% of the Net Offer shall be available for allocation to Non-Institutional Bidders (the "Non-Institutional Portion") out of which (a) one-third of such Non-Institutional Portion shall be reserved for applicants with application size of more than ₹20.00 million and up to ₹1.00 million; and (b) two-third of such Non-Institutional portion shall be reserved for applicants with application size of more than ₹1.00 million provided that the unsubscribed Non Institutional portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. The allocation to each Non-Institutional investor shall not be less than the minimum application size, subject to availability of Equity Shares in the Non-Institutional Portion and the remaining available Equity Shares, if any, shall be allocated on a proportionate basis in accordance with the conditions specified in this regard in Schedule XIII of the SEBI ICDR Regulations. Further not more than 10% of the Net Offer shall be available for allocation to Retail Individual Bidders ("RIBs") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. Further all potential Bidders (except Anchor Investors) are required to mandatorily participate in the Offer through the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective bank accounts (including UPI ID for UPI Bidders using UPI Mechanism) (as defined hereinafter) in which the Bid amount will be blocked by the SCSBs or the Sponsor Banks, under the UPI mechanism as applicable, to participate in the Offer. Anchor Investors are not permitted to participate in the Anchor Investor Portion of the Offer through the ASBA process. For details, see "Offer Procedure" beginning on page 641 of the RHP.

Bidders/Applicants should ensure that DP ID, PAN and the Client ID and UPI ID (for UPI Bidders bidding through UPI Mechanism) are correctly filled in the Bid cum Application Form. The DP ID, PAN and Client ID provided in the Bid cum Application Form should match with the DP ID, PAN, Client ID and UPI ID available (for UPI Bidders bidding through the UPI Mechanism) in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Bidders/Applicants should note that on the basis of the PAN, DP ID, Client ID and UPI ID (for UPI Bidders bidding through the UPI mechanism) as provided in the Bid cum Application Form, the Bidder/Applicant may be deemed to have authorized the Depositories

to provide to the Registrar to the Offer, any requested Demographic Details of the Bidder/Applicant as available on the records of the depositories. These Demographic Details may be used, among other things, for giving Allotment Advice or unblocking of ASBA Account or for other correspondence(s) related to the Offer. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Bidders/Applicants' sole risk.

Investors must ensure that their PAN is linked with Aadhaar and are in compliance with the notification issued by Central Board of Direct Taxes notification dated February 13, 2020 and read with press releases dated June 25, 2021, September 17, 2021 and March 28, 2023 and any subsequent press releases in this regard.

Contents of the Memorandum of Association of our Company as regards its objects: For information on the main objects of our Company, please see "History and Certain Corporate Matters" on page 265 of the RHP. The Memorandum of Association of our Company is a material document for inspection in relation to the Offer. For further details, see "Material Contracts and Documents for Inspection" on page 691 of the RHP.

Liability of the members of our Company: Limited by shares.

Amount of share capital of our Company and capital structure: As on the date of the RHP, the authorised share capital of our Company is ₹ 3,000,000,000 divided into 1,500,000,000 Equity Shares of face value of ₹2 each. The issued, subscribed and paid-up Equity share capital of our Company is ₹ 2,359,514,642 divided into 1,179,757,321 Equity Shares of face value of ₹2 each. For more details of the capital structure of the Company, see "Capital Structure" beginning on page 118 of the RHP.

Names of the initial signatories to the Memorandum of Association of the Company and the Number of Equity Shares Subscribed by them: The initial signatories to the Memorandum of Association of the Company are as follows: Dr. Ranjan Ramdas Pai and Rangarajan Venkatachari who had each subscribed to 5,000 equity shares of face value of ₹10 each. For more details of the share capital history of our Company please see "Capital Structure" beginning on page 118 of the RHP.

Listing: The Equity Shares that will be offered through the Red Herring Prospectus are proposed to be listed on the Stock Exchanges. Our Company has received 'in-principle' approvals from BSE and NSE for the listing of the Equity Shares pursuant to their letters each dated June 9, 2026, respectively. For the purposes of the Offer, the Designated Stock Exchange shall be NSE. A signed copy of the Red Herring Prospectus has been filed and a signed copy of the Prospectus shall be filed with the RoC in accordance with Sections 26(4) and 32 of the Companies Act, 2013. For details of the material contracts and documents available for inspection from the date of the Red Herring Prospectus until the Bid/ Offer Closing Date, see "Material Contracts and Documents for Inspection" on page 691 of the RHP.

Disclaimer Clause of Securities and Exchange Board of India ("SEBI"): SEBI only gives its observations on the draft offer documents and this does not constitute approval of either the Offer or the specified securities stated in the Offer Documents. The investors are advised to refer to page 614 of the RHP for the full text of the disclaimer clause of SEBI.

Disclaimer Clause of BSE: It is to be distinctly understood that the permission given by BSE should not in any way be deemed or construed that the Red Herring Prospectus has been cleared or approved by BSE nor does it certify the correctness or completeness of any of the contents of the Red Herring Prospectus. The investors are advised to refer to the page 618 of the Red Herring Prospectus for the full text of the disclaimer clause of BSE.

Disclaimer Clause of NSE (the Designated Stock Exchange): It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to page 619 of the RHP for the full text of the disclaimer clause of NSE.

General Risks: Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have neither been recommended, nor approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the Bidders is invited to "Risk Factors" on page 34 of the RHP.

Continued on next page...

...continued from previous page.

BOOK RUNNING LEAD MANAGERS			
 Kotak Investment Banking Kotak Mahindra Capital Company Limited 1st Floor, 27 BKC, Plot No. C - 27, "G" Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Maharashtra, India Tel: +91 22 4336 0000 E-mail: manipal ipo@kotak.com Website: https://investmentbank.kotak.com Investor Grievance ID: kmccredressal@kotak.com Contact Person: Ganesh Rane SEBI Registration Number: INM000008704	 AXIS CAPITAL Axis Capital Limited 1st Floor, Axis House, Pandurang Budhkar Marg Worli, Mumbai - 400 025 Maharashtra, India Tel: + 91 22 4325 2183 E-mail: manipalhospitals ipo@axiscap.in Website: www.axiscapital.co.in Investor Grievance ID: kmccredressal@axiscap.in Contact Person: Sagar Jatakiya SEBI Registration Number: INM000012029	 Goldman Sachs Goldman Sachs (India) Securities Private Limited 9th and 10th Floor, Ascent-Worli, Sudam Kalu Ahire Marg, Worli Mumbai - 400 025 Maharashtra, India Tel: +91 22 6616 9000 E-mail: gs-manipal@gs.com Website: www.goldmansachs.com Investor Grievance ID: india-client-support@gs.com Contact Person: Achint Parmanandkar/ Siddhant Choudhary SEBI Registration Number: INM000011054	 Jefferies Jefferies India Private Limited Level 16, Express Towers, Nariman Point, Mumbai - 400 021 Maharashtra, India Tel: +91 22 4356 6000 E-mail: Manipal.IPO@jefferies.com Website: www.jefferies.com Investor Grievance ID: jipl.grievance@jefferies.com Contact Person: Akshat Shah/ Saiyam Sanghvi SEBI Registration Number: INM000011443
BOOK RUNNING LEAD MANAGERS		REGISTRAR TO THE OFFER	COMPANY SECRETARY AND COMPLIANCE OFFICER
 UBS UBS Securities India Private Limited Level 29, Altimus, Dr. G.M Gokhale Marg, Pandurang Budhkar Road, Worli, Mumbai - 400 018, Maharashtra, India Tel: +91 22 6233 6019 E-mail: ol-manipalhospitalsipo@ubs.com Website: www.ubs.com/indiaoffers Investor Grievance ID: igmbindia@ubs.com Contact Person: Devendra Sethia SEBI Registration Number: INM000013101	 DBS DBS Bank India Limited Ground Floor, Express Towers, Nariman Point, Mumbai 400 021 Maharashtra, India Tel: +91 44 6632 8000 E-mail: Manipal.IPO@dbis.com Website: https://go.dbis.com/ipo Investor Grievance ID: investor.grievance@dbis.com Contact Person: Sanjog Kusumwal/ Rutvik Pawgi SEBI Registration Number: INM000012892	 KFINTECH KFin Technologies Limited Selenium Tower B, Plot No. 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy - 500 032, Telangana, India Tel: +91 40 6716 2222/ 180 0309 4001 E-mail: manipal.ipo@kfintech.com Website: www.kfintech.com Investor Grievance ID: einward.ris@kfintech.com Contact Person: M. Murali Krishna SEBI Registration Number: INR000000221	 J.P.Morgan J.P. Morgan India Private Limited J.P. Morgan Tower, Off CST Road, Kalina Santacruz East Mumbai - 400 098, Maharashtra, India Tel: +91 22 6157 3000 E-mail: Manipal_Hospitals_IPO@jpmorgan.com Website: www.jpmlpl.com Investor Grievance ID: investorsmb.jpmpl@jpmorgan.com Contact Person: Darshil Mehta SEBI Registration Number: INM000002970

*DBS Bank India Limited is deemed to be an "associate" of Imperius Healthcare Investments Pte. Ltd. (one of our Promoters and Selling Shareholders) in terms of Regulation 21A of SEBI Merchant Bankers Regulations and has undertaken to be associated only with respect to the marketing of the Offer in compliance with Regulation 21A of SEBI Merchant Bankers Regulations. Further, DBS Bank India Limited has signed the due diligence certificate and has been disclosed as a Book Running Lead Manager in the Red Herring Prospectus.

AVAILABILITY OF THE RHP: Investors are advised to refer to the RHP and the **"Risk Factors"** beginning on page 34 of the RHP before applying in the Offer. A copy of the RHP will be made available on the website of SEBI at www.sebi.gov.in and is available on the websites of the BRLMs, Kotak Mahindra Capital Company Limited at : <https://investmentbank.kotak.com>, Axis Capital Limited at www.axiscapital.co.in, Goldman Sachs (India) Securities Private Limited at www.goldmansachs.com, Jefferies India Private Limited at www.jefferies.com, J.P. Morgan India Private Limited at www.jpmlpl.com, UBS Securities India Private Limited at www.ubs.com/indiaoffers and DBS Bank India Limited at <https://go.dbis.com/ipo> and at the website of the Company, Manipal Health Enterprises Limited at www.manipalhospitals.com and the websites of the Stock Exchanges, for BSE Limited at www.bseindia.com and for National Stock Exchange of India Limited at www.nseindia.com.

AVAILABILITY OF THE ABRIDGED PROSPECTUS: A copy of the Abridged Prospectus shall be available on the website of the Company, the BRLMs and the Registrar to the Offer at : www.manipalhospitals.com, <https://investmentbank.kotak.com>, www.axiscapital.co.in, www.goldmansachs.com, www.jefferies.com, www.jpmlpl.com, www.ubs.com/indiaoffers, <https://go.dbis.com/ipo> and www.kfintech.com, respectively.

AVAILABILITY OF BID CUM APPLICATION FORM: Bid cum Application Form can be obtained from the Registered Office of our Company, Manipal Health Enterprises Limited, Tel: +91 80 4936 0300; **BRLMs:** Kotak Mahindra Capital Company Limited, Tel: +91 22 4336 0000, Axis Capital Limited, Tel: +91 22 4325 2183, Goldman Sachs (India) Securities Private Limited, Tel: +91 22 6616 9000, Jefferies India Private Limited, Tel: +91 22 4356 6000, J.P. Morgan India Private Limited, Tel: +91 22 6157 3000, UBS Securities India Private Limited, Tel: +91 22 6233 6019 and DBS Bank India Limited, Tel: +91 44 6632 8000 and **Syndicate Member:** Kotak Securities Limited Tel: +91 22 4285 8484, Registered Brokers, SCSBs, Designated RTA Locations and Designated CDP Locations for participating in the Offer. Bid cum Application Forms will also be available on the websites of the Stock Exchanges at www.bseindia.com and www.nseindia.com and at all the Designated Branches of SCSBs, the list of which is available on the websites of the Stock Exchanges and SEBI.

SUB-SYNDICATE MEMBERS: Almondz Global Securities Limited, Amrapali Capital & Finance Services Ltd., Anand Rathi Share & Stock Brokers Ltd., Anand Share Consultancy, ANS Pvt Limited, Asit C. Mehta Investment Intermediates Ltd, Axis Securities Limited, Centrum Finverse Ltd, G Raj & Co. (Consultants) Limited, HDFC Securities Limited, IICI Securities Limited, IDBI Capital Markets & Securities Limited, Innovate Securities Pvt Limited, Javen Securities, JM Financial Services Limited, Jobanputra Fiscal Services Private Limited, Kalpataru Multiplier Limited, Keynote Capitals Limited, KJMC Capital Market Services Limited, Lakshminisree Investment & Securities Pvt Ltd, LKP Securities Limited, Marwadi Shares & Finance, Motilal Oswal Financial Services Ltd, Motilal Oswal Securities Limited, Nirmal Bang Securities Pvt. Ltd., Nuvama Wealth and Investment Limited (Edelweiss Broking Limited), Patel Wealth Advisors Pvt Limited, Prabhudas Lilladher Pvt Ltd, Pravin Ratilal Share & Stock Brokers Limited, RR Equity Brokers Pvt Limited, SBICAP Securities Limited, Sharekhan Ltd, SMC Global Securities Ltd, Tanna Financial Services, YES Securities (India) Ltd.

ESCRROW COLLECTION BANK(S): Kotak Mahindra Bank Limited | **REFUND BANK(S):** Kotak Mahindra Bank Limited.

PUBLIC OFFER ACCOUNT BANK(S): Axis Bank Limited. | **SPONSOR BANK(S):** Axis Bank Limited and Kotak Mahindra Bank Limited.

UPI: UPI Bidders can also Bid through UPI Mechanism.

All capitalised terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

Place: Bengaluru
Date: July 23, 2026

For Manipal Health Enterprises Limited
On behalf of the Board of Directors
Sd/-
Sathish Kolar Ramamoorthy
Company Secretary and Compliance Officer

Manipal Health Enterprises Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, an initial public offer of its Equity Shares and has filed a RHP dated July 23, 2026 with the RoC. The RHP is made available on the website of the SEBI at www.sebi.gov.in as well as on the website of the BRLMs i.e., Kotak Mahindra Capital Company Limited at : <https://investmentbank.kotak.com>, Axis Capital Limited at www.axiscapital.co.in, Goldman Sachs (India) Securities Private Limited at www.goldmansachs.com, Jefferies India Private Limited at www.jpmlpl.com, UBS Securities India Private Limited at www.ubs.com/indiaoffers and DBS Bank India Limited at <https://go.dbis.com/ipo>, the website of the NSE at www.nseindia.com and the website of the BSE at www.bseindia.com and the website of the Company at www.manipalhospitals.com. Any potential investor should note that investment in equity shares involves a high degree of risk and should refer to the RHP, including the section titled **"Risk Factors"** beginning on page 34 of the RHP. Potential investors should not rely on the DRHP for making any investment decision.

This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction. The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the **"U.S. Securities Act"**) or any state securities laws in the United States and unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in accordance with any applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold within the United States only to "qualified institutional buyers", as defined in Rule 144A (**"Rule 144A"**) under the U.S. Securities Act, in transactions exempt from or not subject to the registration requirements of the U.S. Securities Act, and outside the United States in "offshore transactions" as defined in, and in compliance with Regulation S (**"Regulation S"**) under the U.S. Securities Act, and in accordance with the applicable laws of the jurisdictions where such offers and sales are being made. There will be no public offering of the Equity Shares in the United States.

CONCEPT

ಕೆಪಿಎಸ್‌ಸಿ ಕರ್ಮಕಾಂಡ ಬಗ್ಗೆ ರಾಹುಲ್ ಮಾತಾಡಲಿ

ವಿವರಗಳು ರಾಷ್ಟ್ರೀಯ ಪರೀಕ್ಷೆ ವಿಷಯದಲ್ಲಿ ರಾಜಕೀಯ ಮಾಡುತ್ತಿವೆ: ಪ್ರಲ್ಹಾದ್ ಜೋಶಿ ಆರೋಪ

ದೆಹಲಿ: ನೀಟ್ ಅಕ್ರಮದ ಬಗ್ಗೆ ಧ್ವನಿ ಎತ್ತಿರುವ ರಾಹುಲ್ ಗಾಂಧಿ ಕರ್ನಾಟಕದ ಕೆಪಿಎಸ್‌ಸಿ ಕರ್ಮಕಾಂಡ ಬಗ್ಗೆ ಏಕೆ ಧ್ವನಿ ಎತ್ತಬೇಕು? ಇದರ ಬಗ್ಗೆ ದ್ವಿಮುಖೀ ನೀಟ್ ಇಂಥಾ ಸೋಲನ್ನು ಎಂದು ಕೇಂದ್ರ ಸಚಿವ ಪ್ರಲ್ಹಾದ್ ಜೋಶಿ ವಾಗ್ದಾನ ನಡೆಸಿದರು. ದೆಹಲಿಯಲ್ಲಿ ಗುರುವಾರ ಮಾಧ್ಯಮದವರೊಂದಿಗೆ ಪ್ರತಿಕ್ರಿಯಿಸಿ, ವಿವರಗಳ ರಾಷ್ಟ್ರೀಯ ಪರೀಕ್ಷೆ ವಿಷಯದಲ್ಲಿ ರಾಜಕೀಯ ಮಾಡುತ್ತಿವೆ ಎಂದು ಆರೋಪಿಸಿದರು.



ಆದರೆ ಒಬ್ಬರ ಅಹಂಕಾರದಿಂದಾಗಿ ಚರ್ಚೆ ಸಾಧ್ಯವಾಗುತ್ತಿಲ್ಲ ಎಂದು ದೂರಿದರು. ವಿವರಗಳು ರಾಜಕೀಯ ಬದಿಗೊತ್ತಿ, ವಿವರಗಳ ಬಗ್ಗೆ ಭವಿಷ್ಯಕ್ಕಾಗಿ ಎಲ್ಲರೂ ಒಪ್ಪಿಗೆ ಚರ್ಚೆಯಲ್ಲಿ ಭಾಗವಹಿಸಬೇಕು ಎಂದು ಪ್ರಲ್ಹಾದ್ ಜೋಶಿ ಕೋರಿದರು. ರಾಹುಲ್ ಮೌನ: ಕೇಂದ್ರದಲ್ಲಿ ಇಷ್ಟೊಂದು ರಾಜಾಂತ ಮಾಡುವ ವಿವರ ನಾಯಕ ರಾಹುಲ್ ಗಾಂಧಿ, ತಮ್ಮದೇ ಆಡಳಿತವಿರುವ ಕರ್ನಾಟಕದಲ್ಲಿ ಕೆಪಿಎಸ್‌ಸಿ ಕರ್ಮಕಾಂಡ ಬಗ್ಗೆ ಏಕೆ ಧ್ವನಿ ಎತ್ತುತ್ತಿಲ್ಲ? ಎಂದು ಜೋಶಿ ಕೆಡಿಕಾರಿದರು. ಕರ್ನಾಟಕದಲ್ಲಿ 2.7 ಲಕ್ಷ ಸರಕಾರಿ ಹುದ್ದೆಗಳು ಖಾಲಿಯಿವೆ, ಕೆಪಿಎಸ್‌ಸಿ ಆದ್ಯಕರ ಮೇಲೆ ಭ್ರಷ್ಟಾಚಾರದ ಆರೋಪಗಳಿವೆ. ಆದ್ದರಿಂದ ಪ್ರತಿಭಟನೆಗಳಿವೆ

ಪರೀಕ್ಷಾಧಿಗಳು ಹಾಗೂ ವಿದ್ಯಾರ್ಥಿಗಳ ಮೇಲೆ ಲಾಠಿ ಚಾರ್ಜ್ ಮಾಡಲಾಗಿದೆ ಹಾಗಿದ್ದರೂ ರಾಹುಲ್ ಆದೇಕೆ ಮೌನ ವಹಿಸಿದ್ದರು. ಅಲ್ಲೇಕೆ ವಿದ್ಯಾರ್ಥಿಗಳ ಹೋರಾಟಕ್ಕೆ ಸಾಥ್ ಕೊಡಲಿಲ್ಲ? ಎಂದು ತೀಕ್ಷ್ಣ ವಾಗ್ದಾನ ಪ್ರತಿಪಾದಿಸಿದ ಜೋಶಿ, ಇದು ಇವರ ದ್ವಿಮುಖೀ ನೀಟಿಯನ್ನೇ ಅನಾವರಣಗೊಳಿಸಿದೆ ಎಂದು ಹರಿಹಾರಿಸಿದರು. ಮಾಜಿಯಾ ವಿರುದ್ಧ ಕಠಿಣ ಕ್ರಮ: ನೀಟ್ ವಿಚಾರದಲ್ಲಿ ಕೇಂದ್ರ ಸರಕಾರ ಯಾವುದೂ ನೆಪ ಹೇಳಿ ಜಾರಿಕೊಂಡಿಲ್ಲ. ವ್ಯವಸ್ಥೆ ಸುಗಮವಾಗಿ ಆದ್ಯತೆ ನೀಡಿದೆ. ನೀಟ್ ಪ್ರಕರಣದಲ್ಲಿ ಈಗಾಗಲೇ 14 ಜನರನ್ನು ಬಂಧಿಸಲಾಗಿದೆ. ರಾಷ್ಟ್ರಮಾಜಿಯಾಗಿ 10 ವರ್ಷ ಕೈಲು ಮತ್ತು ಭಾರೀ ದಂಡ ವಿಧಿಸುವ ಕಟ್ಟುನಿಟ್ಟಿನ ಕಾನೂನನ್ನು ಜಾರಿಗೆ ತಂದಿದೆ ಎಂದು ಕೇಂದ್ರದ ಕ್ರಮವನ್ನು ಪ್ರಲ್ಹಾದ್ ಜೋಶಿ

ವೈದ್ಯ ಸೀಟು 3 ಪಟ್ಟು ಹೆಚ್ಚಳ
2014ರಿಂದ ನರೇಂದ್ರ ಮೊದಲ ಸರಕಾರ, ಭಾರತದ ಯುವಕರು ಅಹರ್ತ ಆಧಾರದ ಮೇಲೆ ಮಾತ್ರ ಅವಕಾಶ ಪಡೆಯುವುದನ್ನು ಖಚಿತಪಡಿಸಿದ. ವೈದ್ಯಕೀಯ ಶಿಕ್ಷಣದಲ್ಲಿ ನಿರ್ವಹಣಾ ಕೋಟಾ ಸೀಟುಗಳ ವ್ಯವಸ್ಥೆ ರದ್ದುಗೊಳಿಸಿತು. ಆದರೆ ವೈದ್ಯಕೀಯ ಸೀಟುಗಳ ಸಂಖ್ಯೆ 2014ರಲ್ಲಿ ಇದ್ದುದರ (51,000) ಮೂರು ಪಟ್ಟು ಇಂದು ಹೆಚ್ಚಾಗಿದೆ ಎಂದು ಉದಾಹರಣೆ ಸಮೇತ ಜೋಶಿ ಸ್ಪಷ್ಟಪಡಿಸಿದರು.

ರಚನಾತ್ಮಕ ವ್ಯವಸ್ಥೆಗೆ ಕೇಂದ್ರ ಬದ್ಧ
ಪ್ರಸ್ತುತ ನೀಟ್ ಪ್ರಶ್ನೆ ಪತ್ರಿಕೆ ಸೋಲಿಕೆ ಸಂಭವಿಸಿದೆ ಎಂದು ಗೊತ್ತಾಗುತ್ತಲೇ ಸರಕಾರ ಪರಿಶ್ಕರಣೆ ರದ್ದುಗೊಳಿಸಿತು. ನಂತರ ಆತ್ಮತೆ ಪಾರದರ್ಶಕ ರೀತಿಯಲ್ಲಿ ಮರು ನೀಟ್ ಪರಿಶ್ಕರಣೆ ನಡೆಸಿತು ಮತ್ತು ಫಲಿತಾಂಶ ಸಹ ತಕ್ಷಣವೇ ಘೋಷಿಸಲಾಯಿತು. ದೇಶದಲ್ಲಿ ಪ್ರಕೃತ ವ್ಯವಸ್ಥೆಯನ್ನು ನಿರ್ವಹಿಸಲು ಬಲಪಡಿಸಲು, ರಚನಾತ್ಮಕ ಸಲಹೆ ಕಾರ್ಯಗಳನ್ನು ಗೊಳಿಸಲು ತಮ್ಮ ಸರಕಾರ ಬದ್ಧವಾಗಿದೆ ಎಂದು ಕೇಂದ್ರ ಸಚಿವ ಪ್ರಲ್ಹಾದ್ ಜೋಶಿ ಪುನರುಚ್ಚರಿಸಿದರು.

ಸಮರ್ಥಿಸಿಕೊಂಡರು. ರಾಜಸ್ಥಾನದಲ್ಲಿ ಗೆನ್ಡೋಟ್ ಅವರ ಅಧಿಕಾರಾವಧಿಯಲ್ಲಿ 19 ಬಾರಿ ಪ್ರಶ್ನೆ ಪತ್ರಿಕೆ ಸೋಲಿಕೆಯಾಗಿದೆ ಎಂದು.

ರಾಜ್ಯದ ಹಲವೆಡೆ ಹೆದ್ದಾರಿ ಟೋಲ್ ದರ ಮತ್ತೆ ಏರಿಕೆ

ಐದು ತಿಂಗಳಿಗಿಂತಲೂ ಕಡಿಮೆ ಅವಧಿಯಲ್ಲಿ ವಿವಿಧ ಟೋಲ್‌ಗಳಲ್ಲಿ ಎರಡನೇ ಬಾರಿಗೆ ಶುಲ್ಕ ಹೆಚ್ಚಳ

ಬೆಂಗಳೂರು: ರಾಜ್ಯದ ಹಲವು ಹೆದ್ದಾರಿಗಳಲ್ಲಿ ಟೋಲ್ ದರಗಳನ್ನು ಹೆಚ್ಚಿಸಲಾಗಿದೆ. ಬೆಂಗಳೂರು-ಮೈಸೂರು ಹೆದ್ದಾರಿ ಹಾಗೂ ಬೆಂಗಳೂರು ಸ್ವಾತಂತ್ರ್ಯ ಟೋಲ್ ರಿಂಗ್ ರೋಡ್‌ನ ಟೋಲ್ ಶುಲ್ಕವನ್ನು ಐದು ತಿಂಗಳಿಗಿಂತಲೂ ಕಡಿಮೆ ಅವಧಿಯಲ್ಲಿ ಎರಡನೇ ಬಾರಿಗೆ ಹೆಚ್ಚಳ ಮಾಡಲಾಗಿದೆ. ಒಂದು ಬಾರಿಗೆ ಹೆದ್ದಾರಿಯಲ್ಲಿ ಸಂಚರಿಸುವ ಕಾರುಗಳ ಪ್ರವೇಶ ಶುಲ್ಕವನ್ನು 355 ರಿಂದ 370 ರು.ಗೆ ಹೆಚ್ಚಿಸಲಾಗಿದೆ. 56.2 ಕಿ.ಮೀ ಅಂತರದ ಕೇಸಿಮೇಟೆ-ಶೇರಿಂಗಿ ಹಳ್ಳಿ ಪ್ರಾಚಾರ ಶುಲ್ಕ 170 ರಿಂದ 185ಕ್ಕೆ ಹೆಚ್ಚಿಸಲಾಗಿದೆ. ಗಣಗೋಡು ಪ್ರಾಚಾರ ಮೂಲಕ ಸಂಚರಿಸುವ ಕಾರುಗಳ ಪ್ರವೇಶ ಶುಲ್ಕವನ್ನು 175 ರಿಂದ 185ಕ್ಕೆ ಹೆಚ್ಚಿಸಲಾಗಿದೆ. ಬೆಂಗಳೂರು-ಮೈಸೂರು ನಡುವೆ ಒಮ್ಮೆ ಹೋಗಿ ಬರುವ ಶುಲ್ಕ 500 ರು. ಆಗಿದೆ. ಲಘು ವಾಣಿಜ್ಯ ವಾಹನಗಳು, ಲಘು ಸರಕು ಸಾಗಣೆ ವಾಹನಗಳು ಹಾಗೂ ಮಿನಿ ಬಸ್‌ಗಳಿಗೆ ಒಂದು ಕಡೆಯ ಸಂಚಾರಕ್ಕೆ 295 ರು., ಎರಡು ಬಾರಿಗೆ 445 ರು.

ನಿಗದಿಯಾಗಿದೆ. ಟ್ರಕ್‌ಗಳು ಮತ್ತು ಬಸ್‌ಗಳಿಗೆ ಒಂದು ಬಾರಿಗೆ 620 ರು., ಎರಡು ಬಾರಿಗೆ 930 ರು. ನಿಗದಿಯಾಗಿದೆ. ಮೂರು ಆಕ್ಸೆಲ್‌ಗಳ ವಾಣಿಜ್ಯ ವಾಹನಗಳು, ಕಟ್ಟಡ ನಿರ್ಮಾಣ ಯಂತ್ರಗಳು ಹಾಗೂ ಆತಿ ಭಾರದ ವಾಹನಗಳ ಪ್ರವೇಶ ಶುಲ್ಕವನ್ನೂ ಹೆಚ್ಚಿಸಲಾಗಿದೆ. ಸ್ವಾತಂತ್ರ್ಯ ಟೋಲ್ ರಿಂಗ್ ರೋಡ್ ಟೋಲ್ ದರ ಏರಿಕೆ: ಅಲ್ಲದೆ, ಸ್ವಾತಂತ್ರ್ಯ ಟೋಲ್ ರಿಂಗ್‌ರೋಡ್‌ನ ದಾಖಲೆಪೇಟೆ-ದೊಡ್ಡಬಳ್ಳಾಪುರ ನಡುವಿನ 80 ಕಿ.ಮೀ. ಸಂಚಾರ ಶುಲ್ಕವನ್ನೂ ಹೆಚ್ಚಿಸಲಾಗಿದೆ. ಹುಲಿಕುಂಟೆ ಟೋಲ್ ಪ್ರಾಚಾರದಲ್ಲಿ ಕಾರು, ವ್ಯಾನ್, ಜೀಪ್ ಸೇರಿ ಲಘು ಮೋಟಾರು ವಾಹನಗಳು ಒಮ್ಮೆ ಸಂಚರಿಸಲು 105 ರ ಬದಲಿಗೆ 110 ರು. ಹಾಗೂ ಎರಡು ಬಾರಿ ಸಂಚರಿಸಲು 165 ರು. ವಾಹನಶೇಖರಣೆ. ನಲ್ಲೂರು ಪ್ರಾಚಾರದಲ್ಲಿ ಒಮ್ಮೆ ಸಂಚರಿಸಲು 85 ರು. ಹಾಗೂ ಎರಡು ಬಾರಿಗೆ 130 ರು. ವಾಹನಶೇಖರಣೆ. ಇತರ ವಾಹನಗಳಿಗೂ ಶುಲ್ಕ ಹೆಚ್ಚಿಸಲಾಗಿದೆ. ಸಗಟು ಬೆಲೆ ಸೂಚ್ಯಂಕಕ್ಕೆ ಅನುಗುಣವಾಗಿ ಕೆಲವು ಏಪ್ರಿಲ್ 1 ರಿಂದ ಶುಲ್ಕ

ಹೆಚ್ಚಿಸಿದ ಬಳಿಕ, ಈಗ ಎರಡನೇ ಬಾರಿಗೆ ಶುಲ್ಕ ಹೆಚ್ಚಿಸಲಾಗಿದೆ. ಬೆಂಗಳೂರು-ಬೇತಮಂಗಲ ಎಕ್ಸ್‌ಪ್ರೆಸ್ ವೇ ಟೋಲ್: ರಾಷ್ಟ್ರೀಯ ಎಕ್ಸ್‌ಪ್ರೆಸ್ ವೇ-7 ರ ಬೆಂಗಳೂರು-ಬೇತಮಂಗಲ ವಿಭಾಗ ಮತ್ತು ಘೆಂ-4 ನಲ್ಲಿ ಇಂಟರ್ ಚೇಂಜ್ ಹೊಂದಿರುವ ಘೆಂ 207 ಕಡೆಯಲ್ಲೂ ಟೋಲ್ ಹೆಚ್ಚಳ ಮಾಡಲಾಗಿದೆ. 70.7 ಕಿ.ಮೀ ಎಕ್ಸ್‌ಪ್ರೆಸ್ ವೇ ಹೊಸಕೋಟೆಯಿಂದ ಬೇತಮಂಗಲದವರೆಗೆ ಸಾಗಿ ಆಂಧ್ರಪ್ರದೇಶದ ಗಡಿಯನ್ನು ತಲುಪುತ್ತದೆ. ಇದು ಹೆಡಗಿನಬೆಲೆ (ಹೊಸಕೋಟೆ ಬಳಿ), ಅಗ್ಗಹಾರ (ಕೋಲಾರ ಜಿಲ್ಲೆಯ ಮಾಲೂರು ಬಳಿ), ಕೃಷ್ಣರಾಜಪುರ (ಬಾಗಲಕೋಟೆ ಬಳಿ) ಮತ್ತು ಸುಂದರವಾಳ್ಕ (ಬೇತಮಂಗಲ ಬಳಿ) 4 ಟೋಲ್ ಪ್ರಾಚಾರಗಳನ್ನು ಹೊಂದಿದೆ. ಕಾರು/ಜೀಪ್/ವ್ಯಾನ್/ಲಘು ಮೋಟಾರು ವಾಹನಗಳು ಈಗ ಹೆಡಗಿನಬೆಲೆ ಟೋಲ್ ಪ್ರಾಚಾರದಲ್ಲಿ ಅಗ್ಗಹಾರದಿಂದ ಬಂದರೆ 50 ರು., ಕೃಷ್ಣರಾಜಪುರದಿಂದ ಬಂದರೆ 120 ರು.

ಮತ್ತು ಸುಂದರವಾಳ್ಕದಿಂದ ಬಂದರೆ 150 ರು. ಶುಲ್ಕ ಪಾವತಿಸಬೇಕಾಗುತ್ತದೆ. ಇನ್ನು ಕೃಷ್ಣರಾಜಪುರದಲ್ಲಿ ಟೋಲ್ ಶುಲ್ಕವನ್ನು ಹೆಡಗಿನಬೆಲೆಯಿಂದ 120 ರು., ಅಗ್ಗಹಾರದಿಂದ 70 ರು. ಮತ್ತು ಸುಂದರವಾಳ್ಕದಿಂದ 30 ರು.ಗೆ ಹೆಚ್ಚಿಸಲಾಗಿದೆ. ಸುಂದರವಾಳ್ಕ ಟೋಲ್ ಪ್ರಾಚಾರದಲ್ಲಿ ಹೆಡಗಿನಬೆಲೆಯಿಂದ 150 ರು., ಅಗ್ಗಹಾರದಿಂದ 95 ರು. ಮತ್ತು ಕೃಷ್ಣರಾಜಪುರದಿಂದ 30 ರು. ಟೋಲ್ ಶುಲ್ಕ ವಿಧಿಸಲಾಗುತ್ತದೆ. ಇನ್ನು ಮಿನಿಬಸ್, ಟ್ರಕ್, ಬಸ್ ಸೇರಿ ಇತರ ವಾಹನಗಳ ಟೋಲ್ ಶುಲ್ಕ ಸಹ ಏರಿಕೆಯಾಗಿದೆ. ಬೆಂಗಳೂರು-ನಲಮಂಗಲ: ರಾಷ್ಟ್ರೀಯ ಹೆದ್ದಾರಿ 48 ರ 19.5 ಕಿ.ಮೀ ಬೆಂಗಳೂರು-ನಲಮಂಗಲ ವಿಭಾಗದಲ್ಲೂ ಟೋಲ್ ಶುಲ್ಕ ಹೆಚ್ಚಳವಾಗಿದೆ. ಕಾರು/ಜೀಪ್/ವ್ಯಾನ್/ಲಘು ಮೋಟಾರು ವಾಹನಗಳಿಗೆ ಪರಿಷ್ಕೃತ ಶುಲ್ಕಗಳು ಒಂದು ಮಾರ್ಗದ ಪ್ರಯಾಣಕ್ಕೆ 105 ರು. ಮತ್ತು 24 ಗಂಟೆಗಳ ಒಳಗೆ ಹಿಂತಿರುಗುವ ದ್ವಿಮುಖ ಪ್ರಯಾಣಕ್ಕೆ 155 ರೂ ನಿಗದಿಪಡಿಸಲಾಗಿದೆ.

ಕುಂಚಿಟಿಗರ ಶ್ರೀ ಒತ್ತಾಯ | ಲಕ್ಷ್ಮೀ ಟೆಕ್ನಿಡಿಯ ಶ್ರೀ ಹಿರೇಮಠದಲ್ಲಿ ಅರ್ಚಕರ ತರಬೇತಿ ಶಿಬಿರ ಉದ್ಘಾಟನೆ

ಉ.ಕ.ದೇಗುಲಗಳ ಅಭಿವೃದ್ಧಿಗೆ ಆದ್ಯತೆ ನೀಡಿ

ಬೆಳಗಾವಿ: ದಕ್ಷಿಣ ಕರ್ನಾಟಕದ ದೇವಾಲಯಗಳ ಮಾರದೆಯಲ್ಲಿ ಉತ್ತರ ಕರ್ನಾಟಕದ ದೇವಾಲಯಗಳನ್ನೂ ಸ್ವಚ್ಛತೆ, ಶಿಸ್ತುಬದ್ಧ ಪೂಜಾ ಪದ್ಧತಿ ಹಾಗೂ ಭಕ್ತಸೇವೆಯ ಮೂಲಕ ಅಭಿವೃದ್ಧಿಪಡಿಸಬೇಕೆಂದು ಕುಂಚಿಟಿಗರ ಸಂಸ್ಥಾನ ಮಠದ ಜಗದ್ಗುರು ಶ್ರೀ ಹನುಮಂತನಾಥ ಮಹಾಸ್ವಾಮೀಜಿ ಹೇಳಿದರು. ಕರ್ನಾಟಕ ದೇವಾಲಯ ಸಂವರ್ಧನಾ ಸಮಿತಿ ಹಾಗೂ ಶ್ರೀ ಗುರುಶಾಂತೇಶ್ವರ ಜಿನಕಲ್ಯಾಣಿ ಪ್ರತಿಷ್ಠಾನ, ಹಿರೇಮಠ-ಹುಕ್ಕೇರಿ ಇವರ ಆಶ್ರಯದಲ್ಲಿ ಬೆಳಗಾವಿಯ ಲಕ್ಷ್ಮೀ ಟೆಕ್ನಿಡಿಯಲ್ಲಿರುವ ಶ್ರೀ ಹಿರೇಮಠದಲ್ಲಿ ಜುಲೈ 21 ರಿಂದ 28ರವರೆಗೆ ಆಯೋಜಿಸಿರುವ ಎಂಟು ದಿನಗಳ ಅರ್ಚಕರ ತರಬೇತಿ ಶಿಬಿರದ ಉದ್ಘಾಟನಾ ಸಮಾರಂಭದಲ್ಲಿ ಅವರು ಮಾತನಾಡಿದರು. ಜನರ ಶ್ರದ್ಧೆ ಮತ್ತು ಭಕ್ತಿ ದೇವಾಲಯಗಳ ಮೂಲಕ ಉದಾತ್ತೀಕರಣಗೊಳ್ಳುತ್ತದೆ. ಪ್ರತಿಮಾ ಆರಾಧನೆಯ ಮೂಲಕ ಸಾಮಾನ್ಯ ಜನರು ದೈವಿಕ ಪ್ರಜ್ಞೆಯನ್ನು ಹೊಂದುತ್ತಾರೆ. ದಕ್ಷಿಣ ಕರ್ನಾಟಕದ ದೇವಾಲಯಗಳು ಸ್ವಚ್ಛತೆ ಹಾಗೂ ಕ್ರಮಬದ್ಧ ಪೂಜಾ ಆಚರಣೆಗಳಿಂದ ಜನಮನ್ನಣೆ ಗಳಿಸುವಂತೆ, ಉತ್ತರ ಕರ್ನಾಟಕದ ದೇವಾಲಯಗಳೂ ಅಭಿವೃದ್ಧಿ ಹೊಂದುವಂತೆ ಉದ್ದೇಶದಿಂದ ಈ ತರಬೇತಿ ಶಿಬಿರವನ್ನು ಆಯೋಜಿಸಲಾಗಿದೆ ಎಂದು ಅವರು ತಿಳಿಸಿದರು. ಇದೇ ವೇಳೆ ಪೂಜಾ ಪದ್ಧತಿ ಕೈಪಿಡಿ ಎಂಬ



ಬೆಳಗಾವಿಯ ಲಕ್ಷ್ಮೀ ಟೆಕ್ನಿಡಿಯಲ್ಲಿರುವ ಶ್ರೀ ಹಿರೇಮಠದಲ್ಲಿ ಎಂಟು ದಿನಗಳ ಅರ್ಚಕರ ತರಬೇತಿ ಶಿಬಿರವನ್ನು ಕುಂಚಿಟಿಗರ ಸಂಸ್ಥಾನ ಮಠದ ಜಗದ್ಗುರು ಶ್ರೀ ಹನುಮಂತನಾಥ ಮಹಾಸ್ವಾಮೀಜಿ ಅವರು ಉದ್ಘಾಟಿಸಿದರು. ಕಿರು ಕೃತಿ ಯನ್ನು ಲೋಕಾರ್ಪಣೆ ಮಾಡಿದರು. ಕಾರಂಜಿ ಮಠದ ಪರಮಪೂಜ್ಯ ಶ್ರೀ ಗುರುಸಿದ್ಧ ಮಹಾಸ್ವಾಮೀಜಿ ದಿವ್ಯ ಸಾನಿಧ್ಯ ವಹಿಸಿ ಅಶೀರ್ವಚನ ನೀಡಿದರು. ಅರ್ಚಕರು ಪೂಜಾ ವಿಧಾನ, ವೇಷಭೂಷಣ ಹಾಗೂ ಮಂತ್ರೋಚ್ಚಾರಣೆಯಲ್ಲಿ ಶುದ್ಧತೆ ಮತ್ತು ಸ್ಪಷ್ಟತೆಯನ್ನು ಕಾಪಾಡಿಕೊಳ್ಳಬೇಕು. ಮಂತ್ರೋಚ್ಚಾರಣೆಯಲ್ಲಿ ದೋಷಗಳು ಉಂಟಾಗದಂತೆ ಎಚ್ಚರ ವಹಿಸುವುದು ಅತ್ಯಗತ್ಯ ಎಂದು ಹೇಳಿದರು. ಮುಖ್ಯ ವಕ್ತಾರ ಶ್ರೀ ಮನೋಹರ ಮಠಜಿ ಮಾತನಾಡಿ, ಅರ್ಚಕನು ದೇವರು ಮತ್ತು ಭಕ್ತರ ನಡುವಿನ ಕೋಡಿಯಾಗಿದ್ದು, ಶುದ್ಧ ಆಂತಃಕರಣ, ಪ್ರಾಮಾಣಿಕತೆ ಹಾಗೂ ಆದರ್ಶ ನಡೆ-ಸುಡಿಗೆಳೆ ಮೂಲಕ ಸೇವೆ ಸಲ್ಲಿಸಿದಾಗ ಮಾತ್ರ ದೇವಾಲಯ, ಭಕ್ತರು ಹಾಗೂ ಸಮಾಜದ ಉನ್ನತಿಗೆ ಕಾರಣನಾಗುತ್ತಾನೆ ಎಂದು ಹೇಳಿದರು. ಕಾರ್ಯಕ್ರಮದ ನೇತೃತ್ವವನ್ನು ಪೂಜ್ಯ ಶ್ರೀ ಚಂದ್ರಶೇಖರ ಶಿವಾಚಾರ್ಯ ಮಹಾಸ್ವಾಮೀಜಿ

ಜನರ ಶ್ರದ್ಧೆ ಮತ್ತು ಭಕ್ತಿ ದೇವಾಲಯಗಳ ಮೂಲಕ ಉದಾತ್ತೀಕರಣಗೊಳ್ಳುತ್ತದೆ. ಪ್ರತಿಮಾ ಆರಾಧನೆಯ ಮೂಲಕ ಸಾಮಾನ್ಯ ಜನರು ದೈವಿಕ ಪ್ರಜ್ಞೆಯನ್ನು ಹೊಂದುತ್ತಾರೆ. ದಕ್ಷಿಣ ಕರ್ನಾಟಕದ ದೇವಾಲಯಗಳ ಸ್ವಚ್ಛತೆ ಹಾಗೂ ಕ್ರಮಬದ್ಧ ಪೂಜಾ ಆಚರಣೆಗಳಿಂದ ಜನಮನ್ನಣೆ ಗಳಿಸುವಂತೆ, ಉತ್ತರ ಕರ್ನಾಟಕದ ದೇವಾಲಯಗಳೂ ಅಭಿವೃದ್ಧಿ ಹೊಂದುವಂತೆ ಉದ್ದೇಶದಿಂದ ಈ ತರಬೇತಿ ಶಿಬಿರವನ್ನು ಆಯೋಜಿಸಲಾಗಿದೆ. -ಜಗದ್ಗುರು ಶ್ರೀ ಹನುಮಂತನಾಥ ಮಹಾಸ್ವಾಮೀಜಿ, ಕುಂಚಿಟಿಗರ ಸಂಸ್ಥಾನ ಮಠ

ವಹಿಸಿದ್ದರು. ಬೆಳಗಾವಿ ಜಿಲ್ಲೆಯ ವಿವಿಧ ಸಮುದಾಯಗಳ ಅರ್ಚಕರನ್ನು ಒಂದೇ ವೇದಿಕೆಗೆ ಕರೆತಂದು ತರಬೇತಿ ಶಿಬಿರ ಯಶಸ್ವಿಗೊಳಿಸಿರುವುದು ಶ್ಲಾಘನೀಯ ಎಂದು ಅವರು ತಿಳಿಸಿದರು. ಕಾರ್ಯಕ್ರಮವನ್ನು ನಗರ ಸಂಘಾಪಾಲಕ ಬಾಳೆಣ್ಣೆ ಕಗ್ಗಣಿಗಿ ಉದ್ಘಾಟಿಸಿದರು. ಉದ್ಯಮಿ ಪಿ.ಎಸ್. ಹಿರೇಮಠ, ವೈದ್ಯರಾಜ ಡಾ. ಎಂ.ಬಿ. ಬೆಲ್ಲದ ಹಾಗೂ ಡಾ. ಕೇದಾರೇಶ್ವರ ಸೇರಿದಂತೆ ಹಲವಾರು ಗಣ್ಯರು ಉಪಸ್ಥಿತರಿದ್ದರು.

ಪಿಜಿಯಲ್ಲಿ ಸಿಲಿಂಡರ್ ಸ್ಫೋಟ: 9 ಕಾರ್ಮಿಕರಿಗೆ ತೀವ್ರ ಗಾಯ



ಆನೇಕಲ್: ಪಿಜಿಯೊಂದರಲ್ಲಿ ಸಿಲಿಂಡರ್ ಅನಿಲ ಸೋರಿಕೆಯಾಗಿ ಸಿಲಿಂಡರ್ ಸ್ಫೋಟಗೊಂಡ ಒಸ್ತೆಯಲ್ಲಿ 9 ಮಂದಿ ಕಾರ್ಮಿಕರು ಗಾಯಗೊಂಡಿರುವ ಘಟನೆ ತಾಲ್ಲೂಕಿನ ಬೊಮ್ಮಸಂದ್ರ ಗ್ರಾಮದಲ್ಲಿ ಶುಕ್ರವಾರ ಬೆಳಿಗ್ಗೆ ನಡೆದಿದೆ. ಖಾಸಗಿ ಕಂಪನಿಯಲ್ಲಿ ಕೆಲಸ ಮಾಡುತ್ತಿದ್ದ ಪತ್ತಿಮ ಬಂಗಾಳಿ ಮೂಲದ ಕಾರ್ಮಿಕರು ಸಂಭವಿಸುವುದಾದ ಭಾರೀ ಅನಾಮತ ಬಂದಿರಲಿಲ್ಲ. ಬೆಳಿಗ್ಗೆ ಕೊಠಡಿಯ ಲೈಟ್ ಅನ್ ಮಾಡುತ್ತಿದ್ದಂತೆ ಅನಿಲ ಸ್ಫೋಟಗೊಂಡು ಬೆಂಕಿ ಹೊತ್ತಿಕೊಂಡಿದೆ ಎನ್ನಲಾಗಿದೆ. ಸ್ಫೋಟದ ತೀವ್ರತೆಗೆ ಮಲಗಿದ್ದ 9 ಕಾರ್ಮಿಕರು ಗಂಭೀರವಾಗಿ ಗಾಯಗೊಂಡಿದ್ದಾರೆ. ಕೂಡಲೇ ಸ್ಥಳೀಯರು ಕಾರ್ಮಿಕರನ್ನು ರಕ್ಷಿಸಿ ಆಸ್ಪತ್ರೆಗೆ ದಾಖಲಿಸಿದ್ದಾರೆ. ಸ್ಫೋಟದಿಂದ ಪಿಜಿಯ ಬಾಗಿಲು, ಕೆಟಕ್ ಪುಡಿಪುಡಿಯಾಗಿದ್ದು, ಮನೆ ಸಂಪೂರ್ಣವಾಗಿ ಜಖಂಗೊಂಡಿದೆ. ಅದ್ಭುತವಾತಾ ಯಾವುದೇ ಪ್ರಾಣ ಹಾನಿ ಸಂಭವಿಸಿಲ್ಲ. ಸ್ಥಳಕ್ಕೆ ಆಗಮಿಸಿದ ವಾಸವಾಗಿದ್ದರು. ರಾತ್ರಿ ಸಿಲಿಂಡರ್‌ನಲ್ಲಿ ಅನಿಲ ಸೋಲಿಕೆಯಾಗಿದ್ದು, ಇದು ಅವರ ಗಮನಕ್ಕೆ ಸಂಭವಿಸುವುದಾದ ಭಾರೀ ಅನಾಮತ ಬಂದಿರಲಿಲ್ಲ. ಬೆಳಿಗ್ಗೆ ಕೊಠಡಿಯ ಲೈಟ್ ಅನ್ ಮಾಡುತ್ತಿದ್ದಂತೆ ಅನಿಲ ಸ್ಫೋಟಗೊಂಡು ಬೆಂಕಿ ಹೊತ್ತಿಕೊಂಡಿದೆ ಎನ್ನಲಾಗಿದೆ.

ಆರೋಪಿಗಳಿಗೆ ಶಿಕ್ಷೆ ಆಗಲಿದೆ

ಪೋಷಕರು ಹೆದರುವ ಅಗತ್ಯವಿಲ್ಲ: ಸಲ್ಮಾನ್ ಖಾನ್

ದೆಹಲಿ: ವಿದ್ಯಾರ್ಥಿಗಳೇ ಯೋಚಿಸದಿರಿ, ಪ್ರಧಾನಿ ಮೊದಲ ಅಭಯ ನೀಡಿದ್ದಾರೆ. ಆರೋಪಿಗಳಿಗೆ ತಕ್ಕ ಶಿಕ್ಷೆ ಆಗುತ್ತೆ, ಪ್ರತಿಭಟನೆ ಕೈಬಿಡುವಂತೆ ಎಂದು ಬಾಲಿವುಡ್ ನಟ ಸಲ್ಮಾನ್ ಖಾನ್ ಮಾತನಾಡಿದ್ದಾರೆ. ಈ ಕುರಿತು ಸೋಷಿಯಲ್ ಮೀಡಿಯಾದಲ್ಲಿ ಪ್ರೋತ್ಸಾಹ ತೀರ ಮಾಡಿದ್ದಾರೆ. ನೀಟ್ ಪ್ರಶ್ನೆಪತ್ರಿಕೆ ಸೋಲಿಕೆ ಎಂಟಿಸಿ ಪ್ರತಿಭಟನೆ ನಡೆಸುತ್ತಿರುವ ವಿದ್ಯಾರ್ಥಿಗಳು ನಿಮ್ಮ ನಿಮ್ಮ ಮನೆಗೆ ಮರಳಿ. ಯೋಚಿಸದಿರಿ, ಪ್ರಧಾನಿ ಮೊದಲ ಅಭಯ ನೀಡಿದ್ದಾರೆ. ಆರೋಪಿಗಳಿಗೆ ತಕ್ಕ ಶಿಕ್ಷೆ ಆಗುತ್ತೆ, ಪ್ರತಿಭಟನೆ ಕೈಬಿಡಿ ಎಂದು ಕೇಳಿಕೊಂಡಿದ್ದಾರೆ. ವಿದ್ಯಾರ್ಥಿಗಳ ತೀಕ್ಷ್ಣ ಮತ್ತು ಭದ್ರತೆ ಆತ್ಮಂತ್ ಮುಖ್ಯ. ಆದ್ದರಿಂದ ವಿದ್ಯಾರ್ಥಿಗಳು ಮತ್ತು ಅವರ ಪೋಷಕರು ಯಾವುದೇ ಕಾರಣಕ್ಕೂ ಹೆದರುವ ಆಗತ್ಯವಿಲ್ಲ. ಪ್ರಧಾನಿ ಮೊದಲಿನಿಂದಲೂ ಬಗ್ಗೆ ಟೀಕ್ ಮಾಡಿದ್ದಾರೆ. ಪ್ರಶ್ನೆಪತ್ರಿಕೆ ಸೋಲಿಕೆಗೆ ಕಾರಣರಾದವರ ವಿರುದ್ಧ ಅವರು

ಪಿಜಿಯ ಆರೋಪವನ್ನು ಕೇಂದ್ರ ಸರಕಾರ ನಿರ್ವಹಿಸಿದ ರೀತಿ ಬಗ್ಗೆ ಯಾವುದೇ ಪ್ರತಿಕ್ರಿಯೆ ನೀಡಲು ಬಯಸುವುದಿಲ್ಲ ಎಂದು ಅವರು ಹೇಳಿದರು, ಆದರೆ ಕೈಗೊಂಡ ಕ್ರಮ ಮಾತ್ರ ಸರಿಯಲ್ಲ ಎಂಬುದನ್ನು ಅವರು ಪುನರುಚ್ಚರಿಸಿದರು. ಅಹಿಂಸೆಯ ತತ್ವದ ಮೇಲಿನ ತಮ್ಮ ನಂಬಿಕೆಯನ್ನು ಅವರು ಪುನರುಚ್ಚರಿಸಿದರು. 'ನಾನು 22 ಉಪವಾಸ ಸತ್ಯಾಗ್ರಹಗಳನ್ನು ನಡೆಸಿದ್ದೇನೆ, ಅವುಗಳಲ್ಲಿ ಎಂದಿಗೂ ಹಿಂಸಾಚಾರ ನಡೆದಿಲ್ಲ' ಎಂದು ಹೆಚ್ಚಾರೆ ಹೇಳಿದರು. ಬಿಜೆಪಿ ನೇತೃತ್ವದ ಕೇಂದ್ರ ಸರಕಾರದ ಪ್ರತಿಭಟನೆಗಳು ಒಂಕರ್ ಮಂಕರ್‌ನಲ್ಲಿ ಪ್ರತಿಭಟನಾಕಾರರನ್ನು ಭೇಟಿ ಮಾಡಬೇಕು ಎಂದು ಅವರು ಒತ್ತಿ ಹೇಳಿದರು. ಪ್ರತಿಭಟನಾಸಾರ್ಥಿ ವಿದ್ಯಾರ್ಥಿಗಳೊಂದಿಗೆ ಮಾತುಕತೆಯಲ್ಲಿ ತೊಡಗಿಸಿಕೊಳ್ಳಲು ಮತ್ತು ಅವರ ಕಳವಳಗಳನ್ನು ಪರಿಹರಿಸುವಂತೆ ಸರಕಾರವನ್ನು ಒತ್ತಾಯಿಸಿದ್ದಾರೆ.

ಪ್ರಧಾನಿಗೆ ಅಣ್ಣ ಹಜಾರೆ ಪತ್ರ

ದೆಹಲಿ: ಸರಕಾರದ ಪ್ರತಿಭಟನಾ ದಮನದ ಕುರಿತು ಹಿರಿಯ ಸಾಮಾಜಿಕ ಕಾರ್ಯಕರ್ತ ಅಣ್ಣಾ ಹಜಾರೆ ಪ್ರಧಾನಿ ಮೊದಲ ಅವರಿಗೆ ಪತ್ರ ಬರೆದಿದ್ದಾರೆ. ಕಾಕೋಟ್ ಜನತಾ ಪಾರ್ಟಿಯ ಪ್ರತಿಭಟನೆಯ ಸಂದರ್ಭದಲ್ಲಿ ನಡೆದ ಹಿಂಸಾಚಾರ ಮತ್ತು ಪೊಲೀಸ್ ಕ್ರಮದ ಕುರಿತು ಪ್ರಸ್ತಾಪಿಸಿದ ಅವರು, ಹಿಂಸಾಚಾರ ಎಂದಿಗೂ ಎಂಬುದನ್ನು ಅವರು ಪೋಷಕರು ಮಾಡಬೇಕು ಎಂದು ಹೆಚ್ಚಾರೆ ತಿಳಿಸಿದರು.

ಪಿಜಿಯ ಆರೋಪವನ್ನು ಕೇಂದ್ರ ಸರಕಾರ ನಿರ್ವಹಿಸಿದ ರೀತಿ ಬಗ್ಗೆ ಯಾವುದೇ ಪ್ರತಿಕ್ರಿಯೆ ನೀಡಲು ಬಯಸುವುದಿಲ್ಲ ಎಂದು ಅವರು ಹೇಳಿದರು, ಆದರೆ ಕೈಗೊಂಡ ಕ್ರಮ ಮಾತ್ರ ಸರಿಯಲ್ಲ ಎಂಬುದನ್ನು ಅವರು ಪುನರುಚ್ಚರಿಸಿದರು. ಅಹಿಂಸೆಯ ತತ್ವದ ಮೇಲಿನ ತಮ್ಮ ನಂಬಿಕೆಯನ್ನು ಅವರು ಪುನರುಚ್ಚರಿಸಿದರು. 'ನಾನು 22 ಉಪವಾಸ ಸತ್ಯಾಗ್ರಹಗಳನ್ನು ನಡೆಸಿದ್ದೇನೆ, ಅವುಗಳಲ್ಲಿ ಎಂದಿಗೂ ಹಿಂಸಾಚಾರ ನಡೆದಿಲ್ಲ' ಎಂದು ಹೆಚ್ಚಾರೆ ಹೇಳಿದರು.

ಬಿಜೆಪಿ ನೇತೃತ್ವದ ಕೇಂದ್ರ ಸರಕಾರದ ಪ್ರತಿಭಟನೆಗಳು ಒಂಕರ್ ಮಂಕರ್‌ನಲ್ಲಿ ಪ್ರತಿಭಟನಾಕಾರರನ್ನು ಭೇಟಿ ಮಾಡಬೇಕು ಎಂದು ಅವರು ಒತ್ತಿ ಹೇಳಿದರು. ಪ್ರತಿಭಟನಾಸಾರ್ಥಿ ವಿದ್ಯಾರ್ಥಿಗಳೊಂದಿಗೆ ಮಾತುಕತೆಯಲ್ಲಿ ತೊಡಗಿಸಿಕೊಳ್ಳಲು ಮತ್ತು ಅವರ ಕಳವಳಗಳನ್ನು ಪರಿಹರಿಸುವಂತೆ ಸರಕಾರವನ್ನು ಒತ್ತಾಯಿಸಿದ್ದಾರೆ.